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ABSTRACT 
Background: 
Vitamin-K antagonists (VKA) are a class of oral anticoagulant medications used to prevent 
blood clots.  The anticoagulant intensity of VKAs is measured with a blood test known as the 
International Normalized Ratio (INR).  Traditionally, international guidelines have 
recommended INR tests every 4 weeks for all patients.  However, adherence to these guidelines 
has never been investigated in real world settings.  The objectives of this study were to describe 
adherence to INR testing in Saskatchewan among patients receiving VKA medications, and to 
identify predictors of optimal adherence. 
Methods: 
This was a retrospective cohort study of VKA users in Saskatchewan captured in the 
administrative data between 2003 and 2010.  Physician claims for anticoagulation monitoring 
were used as a proxy for INR testing.  Adherence to INR testing was measured using the 
Continuous, Multiple-Interval Measure of Medication Gaps (CMG).  Individuals were 
considered adherent if adherence by the CMG was at least 80%.  Hierarchical (random effects) 
logistic regression models were developed to identify important predictors of optimal INR 
monitoring.  Individual physician identification was considered a random effect in these models.  
The dependent variable was the achievement of optimal adherence, defined as ≥80% adherence 
to the 4-week test interval.  
Results: 
Among 17,388 VKA users, 42% resided in rural areas and virtually all (99%) were monitored by 
a general practitioner.  During a median follow-up of 514 days, 50% of patients exhibited at least 
74% adherence to INR testing if a 4-week interval was used as the reference standard.  However, 
the estimated median adherence increased dramatically to 98% when the benchmark for optimal 
testing was lengthened to every 12 weeks.  The most prominent risk factors for poor adherence 
to INR monitoring appeared to be rural residence (rural vs. urban OR 0.55, 95% CI 0.47-0.64 
among subjects age ≥75 years) and duration of VKA therapy (≥731 vs. 35-90 days OR 0.04, 
95% CI 0.03-0.05).      
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Discussion: 
Adherence to INR testing appeared to be acceptable for most VKA-treated patients in 
Saskatchewan.  However, this data indicated that adherence might be more problematic in the 
subgroup of rural residents.  Possible explanations include reduced access to testing facilities or 
the shortage of physicians in rural areas.  Further research is required to understand if poor 
access is the underlying cause of non-adherence to INR testing in the rural population.   
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1 INTRODUCTION 
1.1 Rationale 
For over 60 years, vitamin K antagonists (VKAs) such as warfarin have been the best 
options to manage patients requiring long-term anticoagulation (1).  However, despite its 
therapeutic importance, warfarin is responsible for a large proportion of hospitalizations due to 
adverse drug reactions (2,3).  Recently, new oral anticoagulant medications (NOACs) have 
become available that are not dependent on lab monitoring for maximizing efficacy and safety.  
Consequently, the roles of VKAs are being seriously re-examined, in particular because of their 
additional requirement for ongoing venous blood testing to monitor each individual’s level of 
anticoagulation with the INR (International Normalized Ratio) (4).  Despite extensive research 
into requirements for monitoring and target INR values, little is known about patterns of INR 
testing and their contribution to patient outcomes in real world settings.  
1.2 Purpose 
The purpose of this report is to quantify adherence to INR testing recommendations and 
identify predictors of optimal adherence among VKA-treated patients in Saskatchewan.  
1.3 Objectives 
1. Describe INR monitoring patterns and determine adherence to international guidelines 
2. Identify predictors of optimal adherence to INR monitoring  
1.4 Study Hypotheses 
Objective 1 
The frequency of INR monitoring (as measured by the Continuous, Multiple-Interval 
Measure of Medication Gaps) among VKA users in Saskatchewan will not meet international 
guideline recommendations.  
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Objective 2 
The most significant predictors of optimal adherence to INR monitoring will be older age, 
urban residence, prior stroke, and a diagnosis of atrial fibrillation or prosthetic heart valve 
replacement.  
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2 LITERATURE REVIEW 
Medline was used to search for literature generally related to the research question, using a 
variety of keywords pertaining to adherence, VKA therapy, and INR monitoring.  The reference 
lists of anticoagulation guidelines were reviewed, as well as those of the relevant papers 
identified.   
2.1 Vitamin K Antagonists and the International Normalized Ratio (INR) 
VKAs are oral anticoagulants that reduce the production of vitamin K dependent clotting 
factors in the liver.  By reducing the concentration of circulating clotting factors, VKAs 
essentially reduce the efficiency of the clotting process in the body.  As a result, these 
medications can be used to prevent the formation of clots (thrombi) as well as speed the 
degradation of existing clots that are associated with adverse health effects. However, in contrast 
to their beneficial effects, VKAs can also cause serious bleeding events.  The risk of bleeding 
with VKA therapy is highly influenced by their unpredictable pharmacokinetic properties (1) 
coupled with numerous food and drug interactions (5).  As a result, patients receiving VKAs 
require regular blood testing to ensure that adequate anticoagulation is achieved with minimal 
risk.   
The basis for measuring the intensity of anticoagulation is the test of prothrombin time 
(PT).  The PT test represents the time to clot formation in a sample of blood after the addition of 
promoters such as calcium and thromboplastin.  Because PT is sensitive to changes in the 
concentration of clotting factors, it adequately measures the degree of anticoagulation produced 
by warfarin and other VKAs (1,6).  Due to a high level of variability between different 
thromboplastins (i.e., clot promoters) used in PT tests, the international sensitivity index (ISI) 
was created to standardize the PT to a common international reference, the International 
Normalized Ratio (INR).  The INR represents the anticoagulant activity of VKAs in a manner 
that allows comparison between different laboratories (1).   
For the majority of VKA-treated patients, an INR below 2.0 has been associated with an 
excess risk of thromboembolism (7), whereas an INR above 3.0 is associated with an 
unacceptable risk for bleeding (1,8,9).  Although strict monitoring of VKAs in clinical trials has 
demonstrated that they can be used safely and effectively (10,11), it is not known whether the 
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generalizability of these highly controlled conditions can be consistently applied to real world 
settings (12–15).  Not only do patients have to take the VKA regularly but they also must travel 
to a recognized laboratory on a monthly basis to ensure proper monitoring occurs.  These 
requirements make the use of VKAs relatively more complex than typical medications used in 
outpatient settings; thus the potential for non-adherence to INR monitoring in real world settings 
is high.      
2.2 Major Indications for Anticoagulation 
VKA therapy is indicated for the prevention and treatment of thromboembolism among 
patients with atrial fibrillation (AF) (16,17), venous thromboembolism (VTE) (18), prosthetic 
heart valves (PHV) (19), and those undergoing orthopedic surgeries and other related procedures 
(VTEP) (20). 
2.2.1 Atrial Fibrillation 
Atrial fibrillation (AF) is a heart arrhythmia that increases the risk of cardioembolic 
stroke.  In these patients, ineffective atrial contractions can lead to pooling of blood and 
thrombus (clot) formation within the atrium itself.  These thrombi can dislodge, travel through 
the arterial circulation, and eventually lodge in cerebral blood vessels causing a stroke (21).    
Altogether, AF contributes to approximately 15% of all occurrences of stroke worldwide 
(16), of which a substantial proportion are disabling (22).  Although the prevalence of AF is 
0.4% to 1% in the general population (21,23,24), age is a major risk factor for AF such that its 
prevalence increases to approximately 10% in those 80 years and older  (16,24).  The median age 
of AF patients is approximately 75 years, and an estimated 70% of all cases are between the ages 
of 65 and 85 years (23).  
AF is commonly associated with structural heart diseases, including heart failure, 
coronary artery disease, hypertension, and valvular heart disease. Nonvalvular AF refers 
specifically to the disease in the absence of rheumatic mitral valve disease, a prosthetic heart 
valve, or mitral valve disease (21).  Valve disease further increases the risk of stroke with AF.  In 
the Framingham Heart Study, AF associated with rheumatic heart disease increased the risk of 
stroke 17-fold compared with age-matched controls, and only 5-fold without rheumatic heart 
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disease (25).  However, valvular AF contributes to a small proportion of the overall AF 
population (26,27). 
The risk for stroke in patients with nonvalvular AF is modified by the presence of 
additional independent risk factors.  A simple risk stratification scheme called the CHADS2 risk 
score is often used by healthcare professionals to estimate an individual patient’s risk of stroke 
from AF.  Risk factors in this scheme include: heart failure, hypertension, age 75 or greater, 
diabetes mellitus, and prior stroke or transient ischemic attack (carrying double the risk).  In 
patients with AF the annual rate of stroke ranges from 1.9% (95% CI 1.3 to 1.7%) to 18.2% 
(95% CI 10.5 to 27.4%) depending on the number and type of risk factors present (28).  Given 
the variable risk of stroke associated with AF, not every patient will experience a net benefit 
from anticoagulation therapy.  Therefore, VKA therapy is indicated only when one or more risk 
factors for stroke are present in addition to AF.  In these cases, lifelong therapy is usually 
recommended at a target INR range between 2.0 to 3.0 (16,17,29). 
For the primary prevention of stroke with AF, dose-adjusted warfarin provides 
approximately a 2.7% absolute reduction in the annual risk of stroke compared to placebo.  In the 
secondary prevention of stroke, warfarin provides an annual risk reduction of 8.4%.  Overall, 
warfarin provides about a 64% (95% CI 49% to 74%) relative risk reduction in stroke compared 
to placebo.  Furthermore, compared to antiplatelet therapy, warfarin provides an additional 39% 
(95% CI 22% to 52%) reduction in risk (22). 
2.2.2 Acute Venous Thromboembolism 
Venous thromboembolism (VTE) is a disease encompassing both deep vein thrombosis 
(DVT) and pulmonary embolism (PE).  DVT is a condition resulting from an apparent 
inappropriate clot formation in the deep veins of the leg.  These large clots can produce swelling, 
pain, and even long term damage to the veins themselves.  Similar to AF, these clots can break 
apart or dislodge and travel up the venous circulation until getting wedged in a pulmonary artery, 
blocking oxygen transfer by the lung.  This situation is termed a PE and can be fatal in a high 
proportion of cases.  Although VTE can occur in young, otherwise healthy individuals, they are 
more frequent when risk factors are present (30,31).  These include multiple trauma, major 
surgery, prolonged immobilization, and hypercoagulable disorders amongst others (6).  The 
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annual incidence of symptomatic VTE is approximately 0.1% in the general population, and 
increases with age (32).  
Following an acute episode of VTE, immediate and full anticoagulation is required to 
prevent thrombus extension and embolization (6).  In addition, continued VKA therapy is 
required to reduce the risk of future events (30).  The risk of a second VTE is lowest when the 
initial event occurred in the presence of a major transient risk factor such as surgery, 
hospitalization, or cast immobilization (30).  It has been estimated that the rate of recurrence is 
only 0.7% per year after stopping anticoagulant therapy for a VTE associated with a surgical risk 
factor; while VTE recurrence associated with a non-surgical risk factor is estimated to be 4.2% 
per year (33).  The risk of VTE recurrence is highest, however, when there is no identifiable risk 
factor associated with the initial event (i.e., unprovoked) (33,34).  The rate of recurrence, in this 
case, is estimated to be 7.4% per year; corresponding to a rate ratio of 2.5 (95% CI 2.0 to 3.2) at 
1 year compared to a VTE provoked by any transient risk factor (33).  It is for these reasons that 
only 3 months of anticoagulation with a VKA is recommended following a VTE associated with 
a transient risk factor, while indefinite treatment may be required following an unprovoked VTE.  
In both cases, however, the target INR is between 2.0 to 3.0 (18).   
The effectiveness of VKA therapy in the treatment of VTE is well demonstrated by trials 
comparing short-term anticoagulation, for 4 or 6 weeks, to intermediate durations of 3 or 6 
months.  Extending the duration of anticoagulation reduces the risk of recurrent VTE by 
approximately one half (RR 0.53, 95% CI 0.40 to 0.70) (30).  
2.2.3 Prevention of Venous Thromboembolism 
Venous thromboembolism is a major complication in hospitalized patients undergoing 
major orthopedic surgery (total hip or knee replacements and hip fracture surgery).  Without 
thromboprophylaxis, the incidence of symptomatic VTE following total hip replacement is 
estimated to range between 2% to 5%, and fatal PE occurs at a rate of 0.1% to 2.0% (31). 
Adjusted-dose warfarin, to a target INR between 2.0 to 3.0, is one option recommended 
for primary thromboprophylaxis after major orthopedic surgeries (20).  In this role, VKAs have 
been estimated to reduce the risk of DVT by 44% (RR=0.56, 95% CI 0.37 to 0.84) and the risk 
of clinical PE by 77% (RR=0.23, 95% CI 0.09 to 0.59). Another class of anticoagulants, low-
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molecular weight heparins (LMWH), are even more effective than VKAs for this indication, but 
have to be administered by injection (31,35).  Regardless of which anticoagulant is used, 
thromboprophylaxis is only required for 10 to 35 days after orthopedic surgeries (20).  
The Canadian Joint Replacement Registry (CJRR) reports that between 2003 and 2007 
there has been a substantial decline in the use of warfarin following major orthopedic surgeries 
(from 39% to 22% of hip replacements, and from 39% to 25% of knee replacements).  During 
the same time period, the use of low-molecular weight heparins has increased from 65% to 74% 
following hip replacement surgeries, and from 63% to 73% following knee replacements.  The 
CJRR report suggests that this might be explained by the need for INR monitoring with warfarin 
therapy.  Furthermore, blood monitoring has likely become even less desirable as the length of 
hospital stays has decreased following joint replacement surgeries (36).  
2.2.4 Prosthetic Heart Valves 
Valve replacement, with either mechanical or bioprosthetic valves, is indicated in the 
treatment of numerous congenital and acquired valvular heart diseases (37,38).  The prevalence 
of valve disease is approximately 2.5% in the general population, and increases with age.  
Between the ages of 18 to 44 years, the estimated prevalence is 0.7%, rising to 13.2% for those 
75 years and older (39).  
Mechanical prosthetic heart valves are associated with a lifetime risk of thromboembolic 
complications, estimated to be as high as 22% per year with no anticoagulation (40).  However, 
an individual’s risk for thromboembolic events varies with the valve position and the type of 
prosthetic used (40).  The annual rate of thromboembolism among anticoagulated patients has 
been estimated to be 0.5% with bileaflet valves, 0.7% with tilting-disk valves, and 2.5% with 
caged-ball or disk valves.  The corresponding annual rate with valves positioned in the aortic 
position is 0.5%, increasing to 0.9% in the mitral position, and to 1.2% with valves in both 
positions (41).  
The American College of Chest Physicians recommends life-long anticoagulation with 
warfarin, at a target INR between 2.0 to 3.0, for most mechanical valves in the aortic position.  
This target is increased to 2.5 to 3.5 for most valves in the mitral position, given the higher 
thromboembolic risk they carry (19).  While the recommended INR range for the less commonly 
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used caged-ball valve is also 2.5 to 3.5 (40), it has been suggested that the optimal range may be 
as high as 4.0 to 4.9 (41).  
Unlike mechanical valves, the rate of thromboembolic events with bioprosthetic valves is 
only high in the first 3 months following surgery, but decreases thereafter (42). For this reason, 
guidelines only recommend anticoagulant therapy for the first 3 months following replacement 
with a bioprosthetic valve in the mitral position (19). 
2.3 Bleeding Risk with Vitamin K Antagonist Therapy 
Although VKAs effectively reduce the risk for thrombus formation, they also increase the 
risk of bleeding (1).  Bleeding is the most common and severe complication associated with 
anticoagulant therapy (43,44).  Major bleeding is of particular interest, and includes events that 
are fatal, life-threatening, result in long-term complications, or consume considerable healthcare 
resources (44).  There is a special emphasis on the occurrence of intracranial hemorrhages (ICH) 
(43) because these are much more likely to result in death or disability compared to extracranial 
hemorrhages (p<0.001), and are associated with approximately a 50% case fatality rate (45).  
However, the most common major bleeding events associated with VKAs originate from the 
gastrointestinal (GI) tract.  These GI bleeds account for approximately 60% of all cases of VKA 
bleeding (8,13). 
In a pooled analysis of early clinical trials, the rate of major bleeding was 1.3% per year 
with warfarin therapy compared to 1.0% per year with placebo.  The corresponding annual rates 
of ICH were 0.3% and 0.1%, respectively (46).  Similar results were observed in a large 
observational study, which reported annual rates of 1.5% for major bleeding and 0.5% for ICH 
(13).  The rate of bleeding is substantially increased by several risk factors, however, including 
the intensity of anticoagulation (i.e., level of INR), the length of therapy, certain patient 
characteristics, and interacting medications (43). 
The risk of bleeding at different anticoagulation intensities was evaluated in a recent 
meta-analysis.  This study observed that the absolute risk of major bleeding increased from 1.4% 
per year at an INR of 2 to 3, to 3.7% per year at an INR of 3 to 5 (9).  The risk of bleeding has 
also been found to be highest near the beginning of therapy (43), as demonstrated by an 
observational study that found approximately a three-fold increased risk of bleeding in the first 3 
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months of therapy (12).  Age has also been commonly associated with bleeding risk (43).  
Observational studies have found that bleeding risk is increased two to three-fold in patients 80 
years of age and older (12,47).  Lastly, the risk of bleeding is increased with the concurrent use 
of several interacting medications (43).  A large cohort study observed that bleeding risk was 
nearly doubled when warfarin was used in combination with aspirin (HR 1.83, 95% CI 1.72 to 
1.96), tripled when used in combination with clopidogrel (HR 3.08, 95% CI 2.32 to 3.91), and 
nearly quadrupled when all three medications were used together (HR 3.70; 95% 2.89 to 4.76) 
(48).  
2.4 Monitoring Vitamin K Antagonist Therapy 
2.4.1 Frequency of INR Monitoring and Time in Therapeutic Range (TTR) 
The dose-response relationship with VKAs is very poor.  Therefore, when a VKA is 
newly initiated, frequent INR monitoring is necessary to determine the appropriate daily dose for 
each individual.  Generally this involves monitoring several times per week for the initial 1 to 2 
weeks of therapy, and reducing the frequency based on the stability of results.  Until recently the 
American College of Chest Physicians recommended monitoring at an interval of no longer than 
4 weeks for the duration of VKA therapy once a stable dose has been achieved (1).  However, 
the most recent anticoagulation guidelines suggest that patients with a stable INR may be safely 
monitored at intervals as long as 12 weeks (49).  More frequent monitoring should be undertaken 
to investigate aberrant values or to monitor after changes to the patient’s medication regimen, 
diet, or health status (1).   
In clinical settings, the frequency of INR monitoring highly influences the quality of 
anticoagulation control, as measured by the time in the therapeutic range (TTR) (50–53).  The 
TTR is the proportion of days spent within the target range, estimated by interpolating INR 
values between consecutive tests (54).  A systematic review found that studies with frequent INR 
monitoring achieved a greater proportion of time in the target range (53).  VKA-treated patients 
undergoing INR testing every 3 weeks spend approximately 48% of the time in therapeutic 
range, compared to only 41% in patients tested every 5 weeks (p<0.0005 for trend) (52).  
However, there have also been studies suggesting that there is little difference in 
anticoagulation control at monitoring intervals as long as every 14 weeks (55–58).  The most 
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recent of these was a randomized trial of patients with a stable INR, comparing dose assessment 
every 4 weeks to every 12 weeks.  Ultimately they observed no significant difference in TTR 
between the two groups after one year of follow-up (74.1% vs. 71.6%, p=0.020 for 
noninferiority).  However, the patients that were monitored every 12 weeks still underwent blood 
testing every 4 weeks and had regular follow-up with the staff at the anticoagulation clinic.  The 
only difference was that sham INR results, within the therapeutic range, were reported to the 
staff for 2 out of every 3 tests.  The extent to which regular patient contact influenced adherence 
and outcomes in this study is unknown.  Also, patients were only eligilble if they did not require 
any dose adjustments within 6 months prior to the study (i.e., stable).  This comprised 
approximately one-third of patients attending their clinic (55), meaning that these results do not 
apply to the other two-thirds of patients that would still require traditional frequencies of blood 
testing.  However, this study provides preliminary evidence that less frequent monitoring may be 
equally as safe and effective.        
Ultimately, the extent to which the INR is kept in the therapeutic range over time is 
strongly associated with clinical outcomes in patients treated with warfarin (41,50,59,60).  
Patients achieving poor INR control are at greater risk of adverse events compared to those who 
are better controlled (61–63).  In a cohort of patients with VTE, the quartile with the worst INR 
control (TTR <45%) experienced nearly a three-fold risk of recurrent VTE and major bleeding 
than patients in the two highest quartiles of INR control (TTR 65-80% and 80-100%) (61).  
Another study reported that among patients with AF, a 10% increase in time spent out of range 
significantly increased the risk of all-cause mortality (OR 1.29, p<0.001), ischemic stroke (OR 
1.10, p=0.006), and thromboembolic events (OR 1.12, p<0.001) (59).  Ultimately, 
anticoagulation control determines the safety and efficacy of VKAs and is a major consideration 
when comparing VKAs to new oral anticoagulant medications (NOACs)(62,63).  
2.4.2 The Effect of Monitoring Setting on Anticoagulation Control 
Patients on anticoagulation therapy are usually monitored by either specialized 
anticoagulation clinics (ACCs) or by physicians in usual care (UC).  ACCs generally focus on 
the management of anticoagulation only, leaving the patient’s other medical issues to their 
primary care physician(s) (64,65).  There are five anticoagulation clinics offered in 
Saskatchewan, located within the Saskatoon, Regina Qu’Appelle, Five Hills, and Kelsey Trail 
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Health Regions (66, Lamb, Darcy. Personal communication. 2014 October 20). The remainder of 
anticoagulated patients in the province continues to be monitored by prescribers not affiliated 
with ACCs.           
Meta-analyses of studies evaluating anticoagulation control have consistently 
demonstrated superior INR control in ACCs (53,67,68).  Van Walraven et al. reviewed 67 
studies evaluating anticoagulation therapy for any indication, and determined that the mean TTR 
achieved in community practice was significantly lower compared to ACCs (56.7% vs. 65.6%; 
difference -8.3%, 95% CI -4.4 to -12.1%) (67).  Dolan et al. performed a similar analysis on 22 
studies evaluating patients with AF, and again found that patients managed in ACCs spent 
significantly more time in therapeutic range (mean TTR 63.6% vs. 52.3%; difference 11.3%, 
95% CI 0.1 to 21.7%) (53).  A meta-analysis of 6 AF studies conducted in the United States, 
similarly observed that patients managed in UC spent on average 51% of their time in 
therapeutic range compared to 63% in ACCs (difference -11%, 95% CI -2 to -20%) (68).          
Given the consistent evidence in favor of anticoagulation clinics, the American College 
of Chest Physicians recommends systematic and coordinated monitoring in a manner similar to 
that provided by ACCs (1,49).  However, monitoring of anticoagulation is still the responsibility 
of usual care physicians in most parts of the world (64).  In Canada, it has been estimated that as 
many as 95% of anticoagulated patients are managed in UC (69), and that the majority of the 
physicians involved practice in family medicine (64).  For this reason, information on the quality 
of INR monitoring in UC is of particular interest. 
2.4.3 INR Monitoring in Usual Care (UC) 
VKA-treated patients mostly require INR testing at least every 4 weeks for the duration 
of their treatment, although stable patients may be monitored as infrequently as every 12 weeks 
(1,49).  Although many studies report a high frequency of INR testing among VKA-treated 
patients (52,59,64,65,69–81), the vast majority of these settings do not appear to reflect real 
world practice.  In managed care programs, INR testing has been carried out at a frequency of 
every 18 to 22 days (70,71).  Similarly, a mean interval of 15.7 days (SD 18.1) has been reported 
in the academic setting (59).  Other studies conducted in UC have found that approximately 80% 
of patients were monitored at least monthly (52,72,82), and others have reported that patients 
undergo on average at least one INR test per month (73–75,77,82).  
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Overall, the literature suggests that patients are usually monitored at the frequency 
recommended by treatment guidelines.  However, these reports may not be generalizable to busy 
community practices.  For instance, all randomized trials (76,81,83–85) and several 
observational studies have required patient or physician consent prior to enrolling patients 
(64,69,72,86–88).  Furthermore, a number of the population-based studies have collected data 
from commercially insured populations (52,70,71,73–75) and academic centers (59,65,77,89,90).  
These settings may provide care in a more coordinated manner, so the high frequency of INR 
monitoring may not be representative of real world practice. 
Another explanation for the higher rates of monitoring observed in some of these studies 
is the measures that were used.  The calculation of a mean interval or a mean number of tests per 
month does not account for more frequent monitoring as a result of out-of-range values.  
Consequently, a period of more frequent testing could falsely increase the overall estimate of 
adherence to INR monitoring. 
2.4.4 Adherence to INR Monitoring 
The responsibility for adhering to chronic medication regimens ultimately falls on 
individual patients in most outpatient healthcare settings.  Unfortunately, the prevalence of non-
adherence is known to be extremely high regardless of the type of medication prescribed (91).  In 
addition to the requirement for medication adherence, VKA users are also required to regularly 
visit a community or hospital laboratory to undergo INR testing.  As a result, any patient 
receiving VKA therapy has an opportunity to be non-adherent to the drug and/or the ongoing 
testing of INRs.  The high frequency of INR testing among VKA-treated patients reported in 
published studies (52,59,64,69–77) is surprising given the extent of non-adherence to chronic 
medications overall (92).  In addition to the usual barriers to adherence (91,93), it is likely that 
INR testing has specific barriers such as the discomfort of routine venipuncture (67) and 
inconvenience, especially in rural settings where the distance to a laboratory might be great.   
There are three retrospective studies that suggest that non-adherence to INR monitoring 
may be a problem.  The first study observed 40 patients with stable anticoagulation, whose 
monitoring was transitioned from an ACC to UC (78).  In this process, the median time to the 
first INR measurement in UC was 41 days.  However, more surprising was the observation that 
three patients did not have a single INR test in the 6 months of follow-up in UC.  Furthermore, 
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these patients had received extensive education stressing the importance of regular INR testing 
while they were managed at the ACC, suggesting that patients lack the ability to direct their own 
care.  However, this study had a small sample size (n = 40) and every patient had initially been 
managed in an ACC (78).  This suggests the possibility that adherence to INR monitoring could, 
in fact, be even worse in the real world.  
A large population-based study in Ontario has also indicated that there may be a high 
prevalence of non-adherence to INR monitoring (8).  This study captured patients exposed to 
oral anticoagulant therapy using administrative databases, and subsequently assigned them to 
periods of ‘monitored’ and ‘unmonitored’ VKA exposure.  Patients were considered 
‘unmonitored’ when there was an interval greater than 8 weeks in duration between consecutive 
INR tests.  Ultimately, they found that patients were ‘unmonitored’ for 48.5% of the time they 
were considered to be taking warfarin.  This suggests that a substantial proportion of monitoring 
intervals were greater than 8 weeks in duration.  However, the authors point out that because the 
bleeding rates were similar in patients that were unmonitored and those that were unexposed to 
warfarin (1.9 vs. 1.8 events per 100 patient-years), it is possible that a large proportion of the 
unmonitored VKA exposure was a result of temporary discontinuation of therapy (8).  An older 
study similarly observed that 53% of testing intervals exceeded 12 weeks in the UC setting.  
However, this was a single-center study evaluating a relatively small group of patients (n=145) 
(89).             
2.4.5 Predictors of Adherence 
The risk factors for non-adherence to INR monitoring have not been substantially 
investigated in the literature.  Furthermore, current evidence comes from single-center studies of 
specialized clinics (94), also enrolling a small number of subjects (95,96).  Given these 
limitations, very little information is available to understand the predictors of adherence to INR 
monitoring guidelines in the general population.  The adherence literature is typically focused on 
predictors of adherence to medication use.  In fact, a large body of literature has investigated the 
predictors of adherence to cardiovascular medications.  Although the relationship between 
adherence to INR monitoring and adherence to cardiovascular medications is unknown, these 
studies may serve as a useful guide to derive hypotheses about possible factors that may be 
important.    
 14 
Demographic factors that have mostly been associated with good adherence to 
cardiovascular (CV) medications include increasing age (94–99) (which has also demonstrated a 
U-shaped relationship (100)), male sex (97,99–101), and higher income (97,100).  There has 
been less consistent evidence to support that a high utilization of healthcare services is a 
predictor of good adherence to CV drugs (95,100–102); however, there are reports of an 
association between adherence and a high frequency of physician visits both before (98,103) and 
after (97) the start of therapy.   
General comorbidity has been inconsistently associated with non-adherence to CV 
medications (95,97,101,102); however, there are several specific disease states more commonly 
associated with improved adherence.  These include a history of diabetes or use of 
antihyperglycemic agents (97,98,100,102,103), and also prior stroke or transient ischemic attack 
(TIA) (96,99,102).  In general, it appears that in the case of statin medications (a cholesterol-
lowering medication), the concurrent use of other CV medications is associated with good 
adherence while noncardiovascular medication use is associated with poor adherence 
(97,98,100).  
Despite the critical importance of INR monitoring for successful (and safe) use of VKA 
medications, little information is available to understand the predictors of monitoring outside of 
specialty clinic settings.  For example, the effect of rural residence may be an important predictor 
of less frequent INR monitoring due to laboratory accessibility and/or availability of healthcare 
providers.  Individuals living in rural settings may have to travel great distances to access 
laboratory testing facilities.  Alternatively, the shortage of rural physicians (104,105) could result 
in less strict monitoring or slower response to undesirable test results.  Although limited access 
to healthcare providers in rural settings is an important barrier to successful chronic disease 
management overall (105), the situation is especially problematic for patients receiving warfarin 
(or other VKA medications).  Failure to ensure regular testing or failure to act upon testing 
results can lead to therapeutic failure (i.e., thromboembolic events) or adverse event (i.e., 
bleeding due to over-anticoagulation) in VKA users (59,61).   
Knowledge about INR testing and its underlying determinants are important for several 
reasons.  For example, NOACs have recently become available in Canada with the advantage of 
predictable dose-response activity, eliminating the need for anticoagulation testing altogether (4).  
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However, coverage for these medications in Saskatchewan has been restricted due to their 
extremely high cost compared to VKA medications (i.e., considering drug costs only)(106).  The 
rationale for restricting NOAC coverage in Saskatchewan was partly based on the assumption 
that equivalent therapeutic benefits can be achieved with VKA medications if INR control is 
optimal.  Presumably, the achievement of optimal INR control requires consistent monitoring; 
thus greater awareness of the predictors of INR monitoring will help inform policy regarding 
coverage of NOAC agents.  
2.5 Summary 
The frequency of INR testing is known to influence anticoagulation control.  Ultimately, 
the extent to which a patient stays in the target range is associated with the risk of bleeding and 
thromboembolism (59).  The current literature mostly reports a high frequency of INR 
monitoring in typical community practice (52,59,64,69–77); however, many of these studies 
originated from targeted providers or institutions and it is doubtful that they represent usual care 
settings.  Adherence to chronic medications is notoriously poor (92), and adherence to INR 
monitoring may be influenced by similar barriers.  To our knowledge, adherence to INR 
monitoring has never been explored in real world settings.    
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3 METHODS 
3.1 Data Source  
The Saskatchewan Ministry of Health collects and maintains health-services data for 
residents in the province who are beneficiaries of government health insurance.  Individual data 
are captured in several different administrative databases, which can be linked through an 
encrypted health services number unique to each resident.  The databases include the Person 
Health Registration System (PHRS), the Vital Statistics Registry (VS), the Prescription Drug 
Database (PDP), the Hospital Discharge Abstract Database (DAD), and the Medical Services 
Database (MSB), among others (107).  
The PHRS includes all residents eligible for Saskatchewan Health benefits. This includes 
over 99% of the population, with the only exceptions being individuals whose healthcare is 
entirely funded by the federal government (i.e., federal inmates, military personnel, and RCMP) 
(107).  This database contains basic demographic information including patient sex and date of 
birth.  It is also updated daily for changes in beneficiary status, such as termination due to death 
or emigration from the province (108).  This file can be linked to Canadian Census data to 
estimate income quintile as well as location of residence (rural or urban) (109).  The VS captures 
information on all births and deaths in the province.  These records include the date of death and 
the cause of death coded by ICD-10 (107).  
The PDP captures outpatient prescription claims for medications listed in the 
Saskatchewan drug formulary.  Although the formulary covers an extensive list of prescription 
medications, it does not capture inpatient drug use, most non-prescription drugs, or professional 
samples (107).  Also, approximately 9% of the population is ineligible for Drug Plan benefits 
because their prescription costs are paid by another government agency (primarily Registered 
Indians) (107,108).  For each dispensation, information is collected on the patient, prescriber, 
drug, and cost.  Drug information includes the drug name, strength, dosage form, dispensing 
date, and the quantity dispensed (108).  However, it does not include information on the 
indication for use, the directions for use, or the days’ supply (107).   
The DAD captures information on every acute care inpatient separation (defined as 
discharge, transfer, or death as an inpatient) and day surgery 
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including any hospitalizations that occur out-of-province (107).  Emergency room visits are not 
captured in this database.  Records include the date of admission and discharge, the specialty of 
the attending physician, up to 25 diagnoses from that visit coded based on the International 
Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Canada 
(ICD-10-CA), and up to 20 procedures performed during the hospital stay coded based on the 
Canadian Classification of Health Interventions (CCI) (108–110).  The diagnosis recorded in the 
first position is considered the most responsible diagnosis for hospital admission (108,109).  
Prior to April 2001 diagnoses were recorded using the coding system of the International 
Classification of Disease, Ninth Revision (ICD-9), and the ICD-10-CA coding system was not 
fully adopted in the province until the 2002/03 fiscal year (109).  Given that we are only 
considering ICD-10-CA codes in our extraction of hospital data (as will be discussed later), we 
will potentially be missing some relevant discharge diagnoses recorded by ICD-9 between 
January 1, 2002 and March 31, 2002.       
The MSB captures claims for all insured physician services in the province.  The data is 
primarily collected from claims submitted by physicians paid on a fee-for-service basis.  
Although salary-paid physicians are required to submit shadow or dummy billings, the 
consistency with which this is done is not known; consequently not all services are captured 
(107,108).  As a result, the available diagnostic information is less complete compared to the 
DAD.  Each medical claim includes an encrypted physician identifier, the date of service, the 
service (billing) codes, and a single three-digit ICD-9 diagnosis code from the visit (108).  Also, 
the physician identifier can be linked to a separate file containing information on each 
physician’s credentials/specialty and dates of registration.  Given that not all of the available 
decimals of the ICD-9 codes are recorded, the diagnosis is also less specific than in the DAD.  In 
addition, the data quality is questionable given that the diagnosis is only provided to support the 
claim for payment (107), and is not intended as a medical record for the patient.  
3.2 Study Design 
This was a population-based retrospective cohort study, created using linked 
administrative databases from the province of Saskatchewan, Canada. 
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3.3 Study Population 
We captured all distinct treatment ‘episodes’ of VKA therapy among beneficiaries of the 
Saskatchewan Prescription Drug Plan between January 1, 2003 and December 31, 2010 (Figure 
3.1).  The index of a VKA treatment ‘episode’ was on the date of the first dispensation (i.e., fill) 
for a VKA following a washout period of at least 150 days where no fills for a VKA are 
recorded.  A washout was used to attempt to capture a similar sample of subjects with new 
exposure to a VKA.  The rationale for using a 150-day washout is based on the definition of the 
discontinuation of therapy, as described in the next section.  The date of the first VKA 
dispensation that satisfied this criterion corresponded to the index date for that episode.  Because 
VKA use can be episodic in nature, subjects may satisfy this inclusion criterion more than once; 
however, we only included the first occurring episode in our analyses.  To enable the 
identification of baseline patient characteristics in the period leading up to the episode, based on 
administrative health data, VKA episodes were also excluded if the patient did not have 
continuous coverage through the Saskatchewan Provincial Drug Plan for at least 365 days prior 
to the index date.  
 
Figure 3.1 Identification of VKA Episodes and Duration of Follow-up 
3.4 Objective 1 - INR Monitoring Patterns and Adherence to the 4-week Testing Interval 
All eligible episodes of therapy were examined descriptively to determine the frequency of 
INR testing during VKA treatment.  Frequency of INR testing was examined in a similar manner 
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as adherence to medications.  Adherence was described overall and also divided into its two 
major sub-types: non-persistence versus non-compliance (defined later).      
3.4.1 Patient Follow-up 
Subjects were followed for the duration of continuous use of VKA therapy  (Figure 3.1).  
Specifically, individuals were followed during the course of an episode of therapy defined from 
their first dispensation for a VKA (index date) until the earliest occurrence of any of the 
following events: discontinuation of the VKA, death, loss of beneficiary status, or the end of the 
observation period (Dec. 31, 2010).  Discontinuation of therapy was defined as a gap between 
VKA dispensations of ≥ 150 days or a gap of ≥ 150 days between the last recorded dispensation 
and the end of available follow-up.  This definition is based on the assumption that any single 
dispensation may supply up to 100 days of VKA medication in Saskatchewan; a 50% grace 
period has been added to assess for late refills (111).  The discontinuation date corresponded to 
the last dispensation preceding the 150-day gap.  This definition ensured that patients continued 
to receive their VKA therapy up until the estimated discontinuation date.  Because some 
dispensations of a VKA may only last 34 days, a stricter definition of continuous VKA use was 
examined in a sensitivity analysis.  Specifically, discontinuation of VKA therapy was established 
if a gap of ≥ 51 days was observed (i.e., rather than 150 days defined in the primary analysis).  
Using this definition, patients were less likely to have temporarily discontinued therapy (i.e., 
negating the need for INR monitoring), which could falsely decrease their measure of adherence 
to INR testing.   
VKA episodes were excluded if only a single VKA fill was obtained or if no 
anticoagulant monitoring claims were recorded during the entire episode (8).  Episodes were also 
excluded if the follow-up was ceased within 35 days of the beginning of therapy.  This criterion 
was required to prevent immortal time bias among individuals with shorter periods of follow-up 
(112).  Specifically, patients cannot mathematically satisfy the conditions for INR non-adherence 
(presented in the next section) if follow-up is shorter than 35 days.  Therefore, these individuals 
would be ‘immortal’ to the endpoint of INR non-adherence (i.e., they would all exhibit 100% 
adherence).  
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3.4.2 Analysis of Adherence to INR Monitoring 
Because a centralized laboratory information database was not yet ready for linkage 
(107), INR testing was estimated from the date of service for an anticoagulant monitoring claim 
(service code 763A) submitted by a physician to the MSB (113).  Overall adherence to INR 
monitoring was calculated using a recognized formula for estimating adherence to medications, 
the Continuous, Multiple-Interval Measure of Medication Gaps (CMG), as described by Steiner 
et al. (114,115).  Specifically, we calculated intervals between consecutive INR testing dates, 
including the interval between the last INR test and the end of each patient’s follow-up (Figure 
3.2).   
In the calculation of the CMG, the number of days between INR testing dates was 
compared against the recommended interval of 34 days (28 days plus a 20% grace period) (103).  
Given that the most recent anticoagulant guidelines suggested that a monitoring interval as long 
as 12 weeks is appropriate among stable VKA users (49), we also calculated adherence to an 84-
day (i.e., 12-week) monitoring interval.  Subsequently, the sum of the number of days exceeding 
each recommended interval represented the ‘INR testing gap’, as opposed to the ‘medication 
gap’ proposed by Steiner et al. (114).  However, in contrast to the original CMG method, we did 
not allow for an accumulation of days covered in situations where the INR was tested at a greater 
frequency than the recommended 4-week interval.  In doing so, frequent testing, especially at the 
start of therapy, was not applied to future gaps to falsely increase the adherence estimate.  
Finally, the CMG for each episode was calculated by summing the total number of days 
in treatment gaps over the period of interest, and dividing it by the total number of days of 
observation in that period.  Adherence was calculated by subtracting the CMG from 1.0 and 
converting the result into a percentage, where a value of 100% reflected complete adherence and 
0% reflected complete non-adherence (116).  Given that the CMG only considers the gaps in 
treatment, it was not possible to have greater than 100% adherence.  
In addition to the overall mean adherence for each episode, we calculated adherence 
independently during the following time periods: 0-3 months, 4-6 months, 7-12 months, 13-24 
months, and >24 months after the initiation of VKA therapy.  In order to be eligible, subjects 
required continuous VKA use over the entire interval being evaluated.  
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Figure 3.2 Measurement of Adherence with the CMG 
3.4.3 Analysis of Persistence to INR Monitoring  
Non-adherence to INR monitoring can occur as a result of infrequent testing (non-
compliance) or from discontinuing INR monitoring altogether (non-persistence) (117).  In order 
to evaluate the contribution of non-persistence to overall non-adherence to INR testing, we 
calculated the interval between the date of the last INR test over the observation period and the 
end of follow-up for each episode of VKA therapy (Figure 3.3).  Any intervals greater than 34 
days in length were assumed to be a result of non-persistence.  In these instances, the date of 
discontinuation of INR monitoring was defined as 34 days after the last INR test, and the 
duration of non-persistence was calculated between the discontinuation date and the end of 
follow-up.  Ultimately, we descriptively analyzed the proportion of non-adherence due to non-
persistence to INR monitoring as well as quantified the duration of time that individuals 
continued their VKA treatment without INR testing.    
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Figure 3.3 Measurement of Period of Non-persistence 
3.5 Objective 2 - Predictors of Adherence to INR Monitoring 
Once adherence was calculated for each episode of VKA therapy, we developed an 
explanatory model to test predictors of optimal monitoring using available data.  Optimal INR 
monitoring was defined as ≥80% adherence calculated using the CMG.  Although this cut-off 
was arbitrary, it is widely used to define optimal adherence to medications (100,102,118).  
Nevertheless, thresholds of 60% and 100% were tested in sensitivity analyses.  
3.5.1 Patient Follow-up 
Subjects were followed from their first dispensation for a VKA for each unique episode 
of therapy (index date) until the earliest occurrence of discontinuation of the VKA (as previously 
described), death, loss of beneficiary status, or the end of the observation period (Dec. 31, 2010).  
It was important to ensure that follow-up of patients was restricted to the period of VKA 
medication use only because INR testing is not necessary after the VKA is discontinued.    
3.5.2 Covariates 
We evaluated the significance of a number of different factors that may influence 
adherence to INR testing among patients receiving VKA medications.  The specific factors were 
organized into three main groups: patient characteristics, physician-related factors, and factors 
specific to anticoagulation therapy.  The specific factors and their rationale for testing are listed 
in Table 3.1.  These variables were mostly selected from the literature based on their association 
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with adherence to warfarin and other cardiovascular medications.  However, given the lack of 
literature pertaining specifically to the prediction of adherence to INR monitoring, additional 
variables were evaluated based on a plausible association with this outcome.       
The specific indication for VKA therapy was also examined as a possible predictor of 
INR adherence.  To do this, each episode of VKA therapy was assigned to one of the following 
diagnostic categories: atrial fibrillation (AF), treatment of venous thromboembolism (VTE), 
prevention of VTE following orthopedic surgery (VTEP), and prosthetic heart valves (PHV).  
Episodes that were associated with more than one of the previous indications, and those with an 
unidentified indication for VKA therapy, were grouped separately to ensure the categories were 
mutually exclusive (Table 3.2).  Case definitions for each diagnosis were determined on or 
before the index date for each episode.  In order to identify the most likely reason that VKA 
therapy was initiated, diagnoses or procedures were only considered if they were recorded within 
30 days or 90 days prior to the first dispensation, depending on the indication being identified.  
Each indication is described as follows.      
Atrial Fibrillation 
 An indication of AF was assigned to episodes with a hospital discharge diagnosis for AF 
(ICD-10-CA I48) in any position in the DAD record within 90 days prior to the index date.  
Alternatively, AF could be identified in the MSB, by a single claim with an ICD-9 diagnosis 
code of 427 within 90 days before the index date.  
 The 90-day screening window to identify outpatient dispensations following a hospital 
discharge diagnosis of AF was used in a large cohort study conducted in Denmark (119).  The 
diagnostic coding of AF is from a validation study of hospital discharges from the Calgary health 
region.  The ICD-10-CA code for AF included in any diagnostic position was found to have high 
sensitivity (98%) and specificity (96%) in a sample of patients diagnosed with stroke (120).  
However, given the association between AF and stroke, these estimates may not be 
representative of the general AF population.  
 The outpatient case definition of AF was based on an observational study in a 
commercially-insured cohort of AF patients in the United States.  In order to identify the 
population with chronic 
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occurring at least six weeks apart (121).  However, we chose to only require a single claim for 
AF.  Reducing the required number of AF claims from two to one has been shown to improve 
sensitivity, while minimally impacting the specificity of an outpatient AF diagnosis (122).  A 
study using medical claims data in Manitoba similarly demonstrated improved sensitivity with a 
reduction in the required number of claims with other cardiovascular diseases (123).   
Treatment of Venous Thromboembolism 
 The indication of VTE was assigned to episodes with a hospital discharge ICD-10-CA 
code for PE (I26.0 to I26.9, O88.2) or DVT (I80.1 to I80.9, I82.1, I82.8, I82.9, O22.3, O22.9, 
O87.1) in any position in the DAD record, or a diagnosis of DVT (ICD-9 451 or 453) or PE 
(ICD-9 415) recorded in the MSB within 30 days prior to the index date.  
The 30-day screening window to identify hospital discharges of VTE was used in an 
observational cohort study in the United States (75).  However, because this study used codes 
from the 9th Revision of the International Classification of Diseases, specific ICD-10 codes were 
obtained from a different study that found a sensitivity of 89% and 58% for identifying 
hospitalized cases of PE and DVT, respectively.  The authors suggested that the low sensitivity 
for capturing hospitalized cases of DVT was likely because the diagnosis is not included when it 
does not change the length of hospital stay or the care received when the patient is hospitalized 
(124).  Given that the low sensitivity for capturing hospital diagnoses of DVT could limit the 
identification of episodes with this indication, the MSB was also screened in order to identify 
subjects managed by outpatient physicians.   
 The MSB was screened for ICD-9 codes derived from a study conducted with the 
medical service claims database in Quebec.  This study determined that the sensitivity of claims 
for DVT was 87% in a 60-day window around the date of the diagnosis, and that the same 
estimate was 78% for PE.  For our purposes, the limitation of these estimates is that the study 
population consisted of patients with a DVT, with or without a concurrent PE diagnosis (125).  
Consequently, the sensitivity of the PE diagnosis may not apply to isolated cases of PE.  
However, these events appear to be consistently captured using hospital discharge data as 
reviewed above.  Another potential limitation was that the study by Tagalakis et al. examined 4-
digit ICD-9 CM codes (125), whereas the Saskatchewan MSB only included 3 digits of the ICD-
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9 coding system.  As a result, it was expected that the corresponding 3-digit codes used in 
Saskatchewan might be less specific.  
Prevention of Venous Thromboembolism 
 A VTEP indication was assigned to VKA episodes following a hospital discharge within 
the previous 30 days, that was associated with one of the following eligible VTEP diagnoses or 
procedures: procedure code for hip replacement (CCI 1.VA.53), knee replacement (CCI 
1.VG.53), or hip fracture surgery (CCI 1.VA.53, 1.VA.74, 1.VC.74, and 1.SQ.53), or with a 
most responsible diagnosis for hip fracture (ICD-10-CA S72.0- S72.2). 
These diagnostic and procedure codes were adopted from the Canadian Joint 
Replacement Registry (CJRR) (36) and the Canadian Institute for Health Information analysis of 
surgical wait times for hip fracture surgery (126).  
Prosthetic Heart Valves 
PHV surgery was assumed for those who were discharged from hospital in the 30 days 
prior to their index date with an associated procedure code for an intervention on the tricuspid 
valve (CCI 1.HS), the pulmonary valve (CCI 1.HT), the mitral valve (CCI 1.HU), or the aortic 
valve (CCI 1.HV)(110).  
This definition was derived on the basis of clinical diagnoses and was reviewed by an 
experienced internal medicine specialist from the Saskatoon Health Region; however, to our 
knowledge it has never been formally validated.  Valve position and type influence the risk of 
thromboembolism and duration of anticoagulation therapy (40).  However, this definition is 
broad, and includes all codes for heart valve repair and replacement, with either bioprosthetic or 
mechanical valves.  Furthermore, these include procedures done on the pulmonary and tricuspid 
valves, which are not explicitly discussed in the anticoagulation guidelines (19).  
Multiple Indications and Unknown Indications 
 The episodes associated with more than one indication specified above were captured in 
the cohort with multiple indications.  The episodes that did not satisfy any of the above criteria 
were categorized as “unknown indication”.  This cohort was descriptively examined to determine 
if additional diagnoses should be added to the existing diagnostic categories (Table 3.2).      
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Table 3.1 Predictors of Adherence to be Tested 
Variable Definition Rationale 
Patient factors  
Age Age in years at index date; 
tested as a continuous and 
categorical variable (binary 
variable – age <75 or ≥75 
years old) 
Clinically important and associated 
with improved adherence to a 
number of therapies (97–99) 
including INR testing (95,96)  
Sex Assigned female or male; 
dichotomous variable 
Clinically important and male sex 
has been associated with better 
adherence to warfarin (101) and 
other drug therapies (97,99,100)  
Urban or rural 
residence 
Subjects residing in a census 
metropolitan area (Saskatoon 
or Regina) or in a census 
agglomeration (Estevan, 
Lloydminster, Moose Jaw, 
North Battleford, Prince 
Albert, Swift Current, or 
Yorkton) (127) were 
considered an urban resident.  
All other subjects were 
considered rural residents. 
Status determined at index 
year; dichotomous variable 
Possible differences in access to 
INR testing and healthcare providers 
(104,105)  
Income Income quintile at index year, 
where Q1 is lowest and Q5 is 
highest income (109). 
Determined from the average 
household income in the 
subject’s dissemination area 
defined by Statistics Canada; 
categorical variable 
Measure of socioeconomic status – 
higher income has been associated 
with adherence to statin (100) and 
antihypertensive (97) drug therapies 
Physician visits 
in prior year Number of outpatient visits in the year prior to the index 
date; tested as a continuous 
variable and categorized into 
quintiles (0 to 11, 12 to 18, 
19 to 25, 26 to 36, ≥37) 
  
Measure of health services 
utilization at baseline associated 
with adherence to statin medications 
(98,103)  
Hospitalizations 
in prior year 
Number of hospitalizations 
(with an overnight stay – to 
exclude day surgeries) in the 
year prior to the index date; 
tested as a continuous and 
Measure of comorbidity and health 
services utilization, associated with 
worse adherence to warfarin (101) 
and statin therapies (99,102)  
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Variable Definition Rationale 
categorical variable (0, 1, 2, 
≥3). 
Charlson index Charlson index (128) based 
on diagnoses in the DAD and 
MSB in the year prior to the 
index date; tested as a 
continuous and categorical 
variable (0, 1, 2, ≥3). 
Measure of comorbidity - poor 
health has been associated with 
worse adherence to warfarin therapy 
(101,129) and other drug therapies 
(97)  
Distinct 
diagnoses in 
prior year 
Number of different 
diagnoses recorded to the 
third digit in ICD-9 and ICD-
10-CA, from the DAD and 
MSB (109), within 365 days 
prior the index date; tested as 
a continuous variable and 
categorized into quartiles (0 
to 6, 7 to 10, 11 to 16, and 
≥17). 
Measure of comorbidity - poor 
health has been associated with 
worse adherence to warfarin therapy 
(101,129) and other drug therapies 
(97)  
Diabetes ≥ 2 claims in the MSB with 
ICD-9 code 250 or ≥ 1 
discharge in the DAD with 
ICD-10-CA code E10 to E14 
in any diagnostic position or 
≥ 1 prescription drug claim 
for an oral diabetic agent or 
insulin (see Appendix) within 
365 days prior to the index 
date (130); dichotomous 
variable 
Associated with adherence to statin 
medications (98,100,103)  
Stroke or 
transient 
ischemic attack 
(TIA) 
Diagnosis in previous 365 
days; identified by a primary 
hospital discharge with an 
ICD-10-CA code of either: 
I60 (excl. 160.8), I61, I63 
(excl. I63.6), I64, H34.1, G45 
(excl. G45.4), H34.0 (131). 
Associated with adherence to 
anticoagulation (96) and statin 
therapies (99,102) 
Number of CV 
medications 
Number of distinct 
cardiovascular (CV) drugs 
with at least one dispensation 
within 180 days prior to the 
index date. This included the 
following medication classes 
(97) from the Saskatchewan 
Drug Formulary (132)(see 
Appendix): antihypertensive 
Associated with adherence to statin 
medications (97,98,100)  
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Variable Definition Rationale 
agents (diuretics, β blocker, 
RAAS agent, CCB), statins, 
other lipid agents, cardiac 
agents, anticoagulants, 
antiplatelets, insulin, oral 
diabetes agents; tested as a 
continuous and categorical 
variable (0, 1, 2, 3, ≥4) 
Number of non-
CV medications 
Number of distinct non-
cardiovascular drugs with at 
least one dispensation within 
180 days prior to the index 
date. This included the 
following medication classes 
(97) from the Saskatchewan 
Drug Formulary (132)(see 
Appendix): antidepressants, 
antipsychotics, 
glucocorticosteroids (oral, 
inhaled, parenteral), 
bisphosphonates, hormone 
replacement therapy, uric 
acid agents, migraine agents, 
NSAIDs, proton pump 
inhibitors, H2-receptor 
antagonists, misoprostol, 
other gastrointestinal agents, 
transplant agents; tested as a 
continuous and categorical 
variable (0, 1, 2, ≥3) 
Associated with non-adherence to 
statin medications (97,98,100)  
Physician factors  
Practitioner 
type (specialist, 
general 
practitioner) 
Type of practitioner 
submitting the greatest 
number of claims for 
monitoring anticoagulation 
(service code 763A)(113) 
over follow-up; as a 
categorical variable 
Possible differences in experience 
monitoring anticoagulation  
Anticoagulation therapy factors 
Indication for 
anticoagulation 
Assigned by cohort 
definitions found in Table 
3.2, into AF, VTE, VTEP, 
PHV, multiple indications, or 
other indication for use; as a 
categorical variable 
Possible differences in comorbidity, 
duration of VKA therapy, and how 
aggressively the patient is treated 
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Variable Definition Rationale 
Duration of 
VKA therapy  
Number of days between 
index and exit dates, stratified 
into the following categories: 
0 to 1, 2 to 3, 4 to 6, 7 to 12, 
12 to 24, and >24 months 
Possibility of consistently high 
adherence in the early phase after 
beginning a VKA episode  
New vs. repeat 
VKA use  
Episodes meeting a 1-year 
washout were classified as 
new use, and all others as 
repeat use (only meeting the 
150-day washout); as a 
dichotomous variable 
Prior warfarin use has been 
associated with poor adherence to 
taking the medication (101,129) 
Index year The year of starting VKA 
therapy; categorized as 2003-
04, 2005-06, 2007-08, 2009-
10. 
First-fill discontinuation of statins 
(102) and antihypertensives (97) 
decreased over time  
 
Table 3.2 Case Definitions of Indications for VKA Therapy 
Data Source Diagnostic Code Time Frame References 
Atrial Fibrillation (AF)* 
MSB ICD-9   
427 
Within 90 days 
before (and 
including) index date 
Sarawate 2006 
(121)  
DAD   ICD-10 CA  
I48 
(any position – 
primary or 
secondary) 
Within 90 days 
before (and 
including) index date 
Hansen 2008 
(119); Kokotailo 
2005 (120)  
Active Venous Thromboembolism (VTE)* 
MSB ICD-9 
451 
453 
415 
Within 30 days 
before (and 
including) index 
Tagalakis 2011 
(125)  
DAD ICD-10 CA 
I26.0 to I26.9 
Within 30 days 
before (and 
including) index date  
Casez 2010 
(124); 
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I80.1 to I80.9, I82.1, 
I82.8, I82.9, O88.2, 
O22.3, O22.9, O87.1 
(any position – 
primary or 
secondary) 
Willey 2004 (75) 
Prevention of Venous Thromboembolism/ Orthopedic Surgery (VTEP) 
DAD Procedure (CCI) 
1.VA.53 
1.VG.53 
1.VA.53, 1.VA.74, 
1.VC.74, and 
1.SQ.53 
 
ICD-10 CA  
S72.0- S72.2 
(primary position 
only) 
Within 30 days 
before (and 
including) index date 
CIHI CJRR 
annual report 
2009 (36); 
CIHI hip fracture 
wait times 2011 
(126)  
Prosthetic Heart Valves (PHV) 
DAD Procedure (CCI) 
1.HS 
1.HT 
1.HU 
1.HV 
Within 30 days 
before (and 
including) index date 
No reference 
found – Codes 
pulled on 
inspection. 
Reviewed by a 
content expert** 
*   Diagnosis can be confirmed with records from either the MSB or DAD 
** Content expert: Dr. Thomas Wilson, MD, FRCPC 
 
3.5.3 Statistical Analysis 
Multiple logistic regression models were built using optimal INR adherence as the 
dependent variable (sensitivity analyses were carried out to evaluate modifications to the 80% 
threshold).   
Prior to model development, each variable was described.  The most appropriate form of 
each variable was explored with a plot of the deciles of the predictor variable against its 
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regression coefficient.  A continuous variable was used when this plot formed a reasonably 
straight line.  All other variables were categorized based on clinical relevance or their 
distribution.  
We then examined correlations between the following variables, using Spearman’s rank-
order correlation coefficient: the comorbidity measures (Charlson index, distinct diagnoses, 
physician visits, hospitalizations, diabetes, stroke, CV and non-CV medications), duration of 
VKA therapy and indication, urban/rural and prior hospital/physician visits, income and 
comorbidity/drug use.  Where variables were found to be highly correlated (i.e., r > 0.5), we 
measured the variance inflation factor (VIF).  Collinearity was assumed if the VIF was greater 
than 10 (133), in which case the preferred variable was chosen based on model fit.  
Given that individual physicians may provide anticoagulant services to several different 
patients, there was the potential for a clustering effect by physician.  To investigate the patient-
level and physician-level characteristics associated with adherence to INR monitoring, we 
conducted hierarchical (random effects) logistic regression analyses.  Individual physician 
identification was considered a random effect in these models.  
First, we fit a null model only containing the physician variable as a random intercept to 
test if the clustering effect by physician was important in the model.  The intraclass correlation 
coefficient (ICC) was used to quantify the clustering effect, and was calculated as follows: ICC = 
VA/(VA + 3.29), where VA is defined as the area level variance (134).  In order to determine if a 
minimum cluster size was required, we compared the ICC to models restricted to clusters with at 
least 3 patients and with at least 5 patients.  
Next, a hierarchical logistic regression model was developed using an empiric approach 
to variable selection.  The purpose of this method was to identify the variables that were 
independently and strongly associated with adherence to INR testing.  To select variables to 
include in the model, we fit a full model that included all available covariates.  From this, a 
reduced model was created by excluding all variables with a p-value > 0.05 for the Wald statistic 
in the full model.  We then removed one variable at a time from the reduced model, and used a 
partial likelihood ratio test (LRT) to confirm its significance in the model (135) at a nominal 
level of significance of α = 0.05.    
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Once the important covariates had been identified, the variables that were originally 
excluded from the full model were added back to the model one at a time to test for confounding 
and for significance in the model.  To assess confounding, we compared the estimated 
coefficients in the reduced model and the full model.  Any coefficient demonstrating a 
considerable change in magnitude (ex. > 20%) suggested that the excluded variable was required 
in the model as a confounder (135). 
Subsequently, we explored specific pairs of variables for interactions.  Poor access to 
healthcare providers in rural communities (104,105) could affect the adherence of the older, 
sicker, and lower income subjects especially.  Given this, we explored the interaction of urban or 
rural residence with age, comorbidity, and income.  We also explored an interaction between 
indication and age, given that there are likely fundamental differences in how anticoagulants are 
prescribed for the different age groups (136–138).  Given the fear of bleeding, practitioners 
might only select anticoagulants for their healthier and motivated elderly patients.  
We assessed the significance of adding one interaction term at a time to the main effects 
model using the LRT (135).  All variables remaining in the model were considered independent 
predictors of adherence to INR monitoring. 
A sensitivity analysis of the definition of optimal adherence (≥ 80%) was performed on 
the full model, using a 60% and 100% adherence threshold.  Consideration was given to whether 
the resulting odds ratios changed the clinical interpretation of each individual variable.   
 All analyses were conducted using PROC GLIMMIX on SAS® software, Version 9.3 
(139).  
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4 RESULTS 
4.1 Indications for New Episodes of VKA Therapy 
Between January 1, 2002 and December 31, 2010 there were 1,352,436 dispensations for 
a VKA in Saskatchewan.  Of these, we identified 44,467 new episodes of VKA therapy among 
35,167 unique individuals (Figure 4.1).  The most common indication for a new episode of 
anticoagulation was AF (34%)(Table 4.1).  The majority of AF cases (51%) were identified in 
the MSB only, while 34% were found in both the MSB and the DAD.  There were 2,553 
episodes (6%) that satisfied criteria for more than one indication.  Again, AF was the most 
common condition among this subgroup (n=1,833; 69%).  
There were 12,921 episodes (29%) that did not meet any of the diagnostic definitions 
previously defined.  Upon review, no predominant diagnosis emerged frequently.  Thirty-three 
percent (4204/12921) of these cases were discharged from hospital in the 30 days preceding the 
index VKA.  However, manual review of all primary diagnosis codes in the DAD did not reveal 
any consistent diseases or conditions.  Similarly, 91% (n=11,820) of episodes were preceded by 
at least one physician visit within 30 days prior to beginning VKA therapy, but manual review of 
ICD codes in the MSB did not reveal any common diagnoses.  Finally, we expanded the criteria 
for an AF diagnosis to include records up to 365 days prior to the index date.  This sensitivity 
analysis identified 2,504 additional AF cases, which only accounted for 19% of all episodes in 
the ‘other’ cohort.          
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Figure 4.1 Flow Diagram of Episode Selection 
Table 4.1 VKA Episodes in Each Disease Cohort 
Cohort Frequency* Percent* 
Atrial fibrillation (AF) 15145 34.06 
Venous thromboembolism (VTE) 6422 14.44 
Prevention of venous thromboembolism (VTEP) 6625 14.80 
Prosthetic heart valve (PHV) 801 1.80 
Multiple indications 2553 5.74 
Other (unknown) indication 12921 29.06 
* Corresponds to number of episodes of VKA therapy, not subjects 
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4.2 Adherence Cohort 
From the 44,467 new episodes, we excluded subjects with < 35 days follow-up (n=12,734), no 
anticoagulant monitoring claims on record (n=22,526), or with fewer than 2 dispensations for a 
VKA (n=8,545).  Ultimately there were 17,388 subjects that were eligible for the adherence 
analysis (Figure 4.1).  Mean age at index was 70.2 years, 52.0% were male, and 57.7% resided in 
urban areas (Table 4.2).  Patients in the AF and VTEP cohorts were older on average (74.4 and 
76.5 years respectively) compared to individuals categorized with other diagnoses.  Also, fewer 
males were observed in the VTEP cohort (27.5%) compared to the other indications.  The total 
number of episodes with a missing value for residence and income was very small (0.7% and 
0.8% respectively).  
The frequency of physician visits and hospitalizations in the year prior to index was 
highest among the subjects with multiple indications for VKA therapy.  Comorbidity, as 
measured by the Charlson index and the number of distinct diagnoses, was also highest in the 
cohort with multiple indications.  Prior stroke or TIA, which can be an important indication for 
VKA therapy in some patients, was observed in 5.7%, and was higher in the cohort with AF and 
an unknown indication (6.7% and 8.7% respectively).  The total number of distinct 
cardiovascular medications filled within 180 days prior to the index date was highest in the AF 
and PHV cohorts, while essentially the opposite was true of the number of non-cardiovascular 
medications.  
Virtually all episodes of VKA therapy (99%) were monitored by a general practitioner 
regardless of diagnostic category.  Also, the majority of new episodes (87.0%) were undertaken 
by patients with no VKA fills in the previous year, while the remaining 13.0% of patients 
received at least one VKA fill between 151 days and 365 days prior to the index date.  The 
percentage of individuals receiving VKAs for the various diagnostic indications was similar 
throughout the study period with the exception of the VTEP cohort, where the proportion of new 
VKA starts declined substantially over time (34.4% in 2003-2004 and 6.3% in 2009-2010).  This 
observation was expected given the national trend of replacing warfarin with low-molecular 
weight heparins over a similar time period (36). 
Characteristics of subjects who were excluded from the adherence analysis were very 
similar to the study population with a few exceptions.  Missing data for physician credentials 
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occurred in only 0.6% of the eligible episodes compared to 69.4% of the ineligible episodes.  
This high proportion can be explained given that 51% of episodes were excluded because they 
had no INR monitoring claim, and therefore no physician could be identified at all.  Lastly, the 
excluded subgroup had a higher percentage of repeat VKA episodes due to the inclusion of only 
a single episode per patient.     
Table 4.2 Patient Characteristics 
Baseline 
Characteristic 
Eligible Subgroupa  Ineligible 
Subgroup 
(N= 27079) 
AF 
(N= 7746) 
VTE 
(N= 3238) 
VTEP 
(N= 512) 
PHV 
(N= 442) 
Multiple 
(N= 1020) 
Other 
(N= 4430) 
All 
(N= 17388) 
Agec, mean 74.37 62.08 76.53 62.17 71.71 68.46 70.18 69.872 
Male sexc , % 53.30 46.79 27.54 65.38 49.51 55.69 52.02 50.02 
Urban, % 
(% missing) 
55.06  
(0.50) 
61.86  
(0.86) 
58.59  
(b) 
53.85 
(b) 
59.12  
(b) 
59.19  
(0.81) 
57.69  
(0.65) 
57.47  
(0.70) 
Income quintilec. %  
1st 18.91 17.88 21.48 b 19.71 17.77 18.38 19.56 
2nd 21.21 21.65 17.19 21.95 22.06 21.92 21.42 20.10 
3rd 23.73 23.69 24.41 24.66 21.47 24.38 23.80 23.07 
4th 19.60 18.62 18.36 22.85 19.12 18.78 19.23 18.99 
5th 15.85 17.23 18.55 17.65 16.67 16.39 16.42 17.33 
Missing 0.70 0.93 0.00 b 0.98 0.77 0.75 0.94 
Physician visitsc, %  
0 to 13 24.50 27.73 9.38 b 4.51 26.91 23.49 20.57 
14 to 19 20.01 17.82 18.75 b 12.16 19.32 18.49 19.26 
20 to 26 19.30 17.91 26.37 18.33 16.76 19.44 19.11 20.11 
27 to 37 19.43 17.23 22.27 42.76 28.43 16.93 19.59 20.16 
≥38 16.76 19.30 23.24 35.75 38.14 17.40 19.32 19.90 
Hospitalizations c, % 
0 35.31 25.32 0.00d 0.00d 3.73 47.27 32.71 31.29 
1 39.44 42.22 52.93 66.29 45.78 30.65 39.17 39.69 
2 14.81 18.31 27.54 21.49 28.73 12.84 16.32 16.40 
≥3 10.44 14.14 19.53 12.22 21.76 9.23 11.80 12.61 
Charlson Indexc, % 
0 37.17 48.98 42.38 25.34 29.02 34.00 37.93 43.74 
1 27.36 19.73 27.73 32.58 27.16 26.39 25.82 23.50 
2 16.67 13.40 15.23 20.59 17.35 b b 14.25 
≥3 18.81 17.88 14.65 21.49 26.47 22.89 20.07 18.42 
Missing 0.00 0.00 0.00 0.00 0.00 b b 0.09 
Distinct diagnoses c, % 
0 to 6 23.04 22.88 9.18 2.94 3.14 28.89 22.42 24.14 
7 to 10 25.10 23.41 22.85 18.33 11.57 25.03 23.73 24.87 
11 to 16 27.18 25.91 32.42 34.84 30.39 24.88 26.89 26.13 
≥17 24.68 27.79 35.55 43.89 54.90 21.20 26.96 24.86 
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Baseline 
Characteristic 
Eligible Subgroupa  Ineligible 
Subgroup 
(N= 27079) 
AF 
(N= 7746) 
VTE 
(N= 3238) 
VTEP 
(N= 512) 
PHV 
(N= 442) 
Multiple 
(N= 1020) 
Other 
(N= 4430) 
All 
(N= 17388) 
Diabetes, % 20.69 13.65 19.14 18.10 17.55 21.24 19.23 18.56 
Stroke/TIAc, 
% 
6.66 1.67 b b 2.16 8.71 5.67 2.65 
Number of distinct cardiovascular drugs dispensed within 180 days prior to the index date^, % 
0 3.78 41.17 20.70 2.04 11.27 15.53 14.63 20.39 
1 11.17 17.70 20.51 10.86 13.33 13.93 13.48 15.69 
2 15.31 14.14 19.14 13.57 16.08 14.54 15.01 15.68 
3 17.87 9.11 14.06 14.71 14.71 13.81 14.83 14.28 
4 16.34 7.32 9.77 18.33 12.65 13.70 13.63 11.89 
≥5 35.53 10.56 15.82 40.50 31.96 28.49 28.42 22.07 
Number of distinct non-cardiovascular drugs dispensed within 180 days prior to the index datec, % 
0 48.04 43.76 27.93 55.66 39.90 46.28 45.92 42.42 
1 28.75 27.61 27.54 26.02 29.80 28.31 28.38 28.64 
2 13.99 15.04 23.83 11.09 17.25 14.81 14.80 16.13 
≥3 9.22 13.59 20.70 7.24 13.04 10.61 10.90 12.81 
Type of practitionere with the most INR claimsc, % 
GP 99.14 98.46 >95b 100.00 99.22 99.07 99.02 30.49 
Specialist 0.19 1.05 b 0.00 b 0.18 0.33 0.08 
Missing 0.67 0.49 b 0.00 b 0.74 0.64 69.43 
New VKA 
usec, % 
87.89 95.52 96.29 >95b 96.37 74.92 87.03 73.86 
Index yearc, % 
2003-2004 27.58 26.44 34.38 24.21 25.29 29.16 27.75 24.03 
2005-2006 26.04 26.04 33.40 23.76 29.12 25.49 26.26 25.05 
2007-2008 24.81 25.29 25.98 25.11 23.63 23.32 24.49 25.63 
2009-2010 21.57 22.11 6.25 26.92 21.96 22.03 21.50 25.29 
Follow-up, % 
0-34 days 0.00 0.00 0.00 0.00 0.00 0.00 0.00 47.03 
35-90 days 6.57 10.07 44.14 36.43 20.59 9.37 10.62 11.44 
91-180 days 9.01 22.98 21.09 9.95 17.75 14.31 13.85 11.75 
181-365 days 14.48 24.18 13.48 8.82 17.06 17.52 17.04 10.60 
366-730 days 18.86 16.46 10.16 11.31 15.00 19.01 17.78 8.71 
≥731 days 51.07 26.31 11.13 33.48 29.61 39.80 40.71 10.47 
a Episodes with ≥1 INR claim, ≥35 days of follow-up, and ≥2 VKA fills 
b Corresponds to a cell size ≤5 
c  Significant p-value (≤0.05) for comparison of eligible and ineligible groups. Significance was determined 
using a t-test for continuous variables and a chi-square test for categorical variables 
d Expected that all subjects have at least one hospitalization, given that the case definition only included hospital 
diagnoses   
e Adherence calculations included all INR monitoring claims (regardless of physician identification or type) 
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4.3 Follow-up 
 The overall mean duration of follow-up was 797.2 (SD 747.5; median 514.0) days using 
a 150-day gap to define the discontinuation of VKA therapy (Table 4.3).  The longest duration of 
follow-up was observed in the AF cohort (mean 952.1, SD 765.4; median 755.0 days), while the 
VTEP cohort had the shortest duration of therapy (mean 306.7, SD 487.9; median 107.5 days).  
This difference is expected because VKA therapy for VTEP is often only used short-term 
following surgical procedures.  The most common reason for study exit was discontinuation of 
VKA therapy (42%).  Sensitivity analysis on the definition of VKA discontinuation influenced 
overall follow-up time significantly.  When using a 51-day gap to define discontinuation, the 
mean duration was shortened to 303.1 (SD 378.3; median 158.0) days (Table 4.3).  By restricting 
follow-up to periods with no more than 51 days between VKA dispensations, it is less likely that 
temporary breaks in VKA therapy were unintentionally captured; thus, leading to 
misclassification of INR non-adherence.    
Table 4.3 Follow-up Using 150-day and 51-day Gaps to Define VKA Discontinuation 
Gap Mean Std. Dev. 
25th 
Percentile Median 
75th 
Percentile Minimum Maximum 
150-day 797.15 747.46 184.00 514.00 1258.00 35.00 >2915** 
51-day  303.05 378.34 77.00 158.00 360.00 35.00 >2756** 
** Corresponds to a cell size ≤5 
4.4 Objective 1 - INR Monitoring Patterns and Adherence to the 4-week Testing Interval 
4.4.1 Adherence 
The median interval to the first INR claim date was 26 days following the first fill of a 
VKA, with a maximum interval greater than 2,618 days (Table 4.4).  Median adherence to INR 
testing corresponding to a recommended interval of four weeks was 74.4% (Table 4.5).  Median 
adherence was highest in the VTEP and PHV cohorts (90.5% and 88.4% respectively), and 
lowest in the AF and ‘other’ cohort (70.9% and 71.6% respectively).  Among all patients in the 
study, the percentage exhibiting optimal adherence was 44.3% (Table 4.6).  
Important differences in the estimates of INR adherence were observed in sensitivity 
analyses.  When the acceptable duration between INR tests was expanded to 12 weeks (i.e., 84 
days) rather than 4 weeks, median adherence increased to 97.8% (Table 4.5).  Also, when patient 
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follow-up was limited to episodes of continuous VKA therapy with no intervals between 
medication dispensations greater than 51 days, median adherence increased to 90.0% (Table 4.7).  
This result was expected given that the 150-day gap (i.e., used in the primary analysis) is more 
likely to inadvertently include periods during which the patient temporarily discontinued therapy 
and did not require monitoring.  
Overall there was a consistent pattern of decreasing adherence over the course of therapy 
(Table 4.8).  Compared to the overall median value (74.4%), adherence was higher in the 
intervals between the index date and 90 days (85.6%) and between 90 and 180 days (80.0%), but 
decreased to as low as 61.7% beyond two years of therapy.   
Table 4.4 Interval Between the Index Date and the First INR Test Date 
Mean Std. Dev. 25
th 
Percentile Median 
75th 
Percentile Minimum Maximum 
121.33 289.40 13.00 26.00 64.00 0.00 >2618** 
** Corresponds to a cell size ≤5 
Table 4.5 Descriptive Statistics of Adherence Measured Using a 4 and 12-week Interval for 
Testing 
Interval Mean Std. Dev. 
25th 
Percentile Median 
75th 
Percentile Minimum Maximum 
34-day  66.35 30.81 41.05 74.42 95.19 <2** 100.00 
84-day  80.27 27.76 65.41 97.82 100.00 <5** 100.00 
  ** Corresponds to a cell size ≤5 
Table 4.6  Proportion of the Cohort who met 60%, 80%, and 100% Adherence Thresholds 
Using a 4-week Interval for Testing 
 Frequency Percent 
≥60% adherence 10889 62.62 
≥80% adherence 7697 44.27 
100% adherence 3127 17.98 
Table 4.7 Descriptive Statistics for Adherence Using a 51 and 150-day Gap to Define VKA 
Discontinuation 
Gap Mean Std. Dev. 
25th 
Percentile Median 
75th 
Percentile Minimum Maximum 
51-day 77.83 27.17 62.50 89.96 100.00 <4** 100.00 
150-day 66.35 30.81 41.05 74.42 95.19 <2** 100.00 
** Corresponds to a cell size ≤5 
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Table 4.8 Descriptive Statistics for Adherence at Intervals After Index Date Using a 4-week 
Interval for Testing 
Days Mean Std. Dev. 
25th 
Percentile Median 
75th 
Percentile Minimum Maximum 
0-90 66.72 40.00 42.22 85.56 100.00 0.00 100.00 
90-180 62.38 42.51 0.00 80.00 100.00 0.00 100.00 
180-365 58.62 39.21 20.54 70.81 98.92 0.00 100.00 
365-730 55.36 37.53 18.63 63.56 92.33 0.00 100.00 
≥730 54.96 36.39 18.18 61.66 89.96 0.00 100.00 
 
4.4.2 Persistence 
 Non-adherence with INR testing can result from long delays between INR tests (i.e., poor 
execution) or complete discontinuation of testing altogether (i.e., non-persistence).  Non-
persistence accounted for a relatively small percentage of overall non-adherence to INR testing 
(mean 22.8%; median 0%)(Table 4.9).  Similarly, the median duration of non-persistence among 
non-adherent episodes was low also (0 days)(Table 4.10).  Persistence was similar in the various 
disease cohorts, and had very little impact on the adherence measurement in all cases.   
Table 4.9 Persistence Among Episodes with Gaps in Testing - Percentage of Total Gaps 
Contributed by the Last Gap 
Mean Std. Dev. 
25th 
Percentile Median 
75th 
Percentile Minimum Maximum 
22.75 35.26 0.00 0.00 36.89 0.00 100.00 
Table 4.10 Duration of Non-persistence (Days) 
Mean 
Std. 
Dev. 
25th 
Percentile 
Median 
75th 
Percentile 
Minimum Maximum 
90.95	   262.11	   0.00	   0.00	   39.00	   0.00	   >2396**	  
** Corresponds to a cell size ≤5 
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4.5 Objective 2 - Predictors of Adherence to INR Monitoring 
4.5.1 Testing for the Clustering Effect by Physician 
Altogether, there were 898 physicians monitoring patients in the cohort and 50% of 
physicians were monitoring at least 10 patients in the study (Table 4.11).  Three hundred-thirty 
physicians (36.8%) followed 5 or fewer patients.  Because small clusters contribute little to no 
variability, it was necessary to determine if restricting the cluster size provided an important 
change to the intraclass correlation coefficient (ICC).  A null model including all subjects and 
cluster sizes resulted in an ICC of 0.34.  There was no change to the ICC when the cluster size 
was restricted to a minimum of 3 and 5 subjects.  Finally, restricting the cluster size to a 
minimum of 50 patients (resulting in 101 clusters) as has been suggested in the literature (140), 
resulted in an ICC of 0.27.  Due to the minimal change of the ICC, it was felt it would be 
appropriate to include all subjects and cluster sizes for further analysis.  Furthermore, given the 
relatively high value of the ICC (0.34), the random physician effect is required in the model to 
control for clustering.   
Table 4.11 Distribution of Physician Cluster Sizes 
Mean Std. Dev. Minimum Median Maximum 19.26	   22.85	   1.00	   10.00	   138.00	  
 
4.5.2 Model Building 
The Wald test statistics for all available covariates in the full model are found in Table 
4.12.  The variables that had the largest effect on the model fit were rural or urban residence 
(p<0.001) and the duration of follow-up (p<0.001).  All of the variables with a significant Wald 
test statistic (p ≤0.05) in the full model were also found to be significant individually and were 
retained.  Although age was not statistically significant, it was ultimately kept in the model for 
clinical interest and to control for possible confounding.  Income quintile (p<0.001) and 
practitioner specialty (p<0.001) substantially improved the model fit when added back to the 
model, and were kept for further analysis.  Although the number of diagnoses and CV drugs both 
modified parameter estimates by approximately 20%, the changes to their respective odds ratios 
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were very small (approximately 2% to 5%).  It was for this reason that these variables were 
ultimately deleted, along with any of the remaining variables.  
Once all the important predictors in the model were identified, each of the pre-specified 
interactions was tested in the model.  The interaction of urban or rural residence with both 
income (p=0.10) and comorbidity (p<0.90) were not significant at α = 0.05.  However, there was 
a statistically significant interaction between age and indication (p<0.025) and also between age 
and rural or urban residence (p=0.025).  
Table 4.12 Test Statistics of Full Model, Including All Variables 
Effect Num DF Den DF F Value Pr > F 
Age 1 16121 1.10 0.2935 
Sex 1 16121 7.51 0.0062 
Urban/Rural 1 16121 67.97 <.0001 
Income quintile 4 16121 1.10 0.3525 
Physician visits 4 16121 5.79 0.0001 
Hospitalizations 3 16121 4.78 0.0025 
Charlson index 3 16121 3.31 0.0191 
Distinct diagnoses 3 16121 2.32 0.0731 
Prior diabetes 1 16121 5.08 0.0242 
Prior stroke 1 16121 2.47 0.1162 
CV drugs 4 16121 0.98 0.4159 
Non-CV drugs 3 16121 4.91 0.0021 
Practitioner type 1 16121 3.10 0.0783 
Indication 5 16121 6.33 <.0001 
Duration of follow-up 4 16121 366.05 <.0001 
New VKA use 1 16121 11.29 0.0008 
Index year 3 16121 4.06 0.0068 
 
4.5.3 Odds of Optimal Adherence 
The odds of achieving optimal adherence to INR monitoring for variables in the empiric 
multivariable model are reported in Table 4.13.  Variables associated with increased odds of 
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adherence to INR monitoring were female sex, a greater number of prior physician visits, and a 
recent index year.  Of these, the number of physician visits in the prior year was the strongest 
predictor (12-18 visits OR 1.15, 95% CI 1.01-1.30; ≥37 visits OR 1.51, 95% CI 1.28-1.77).  The 
odds of adherence were decreased by the number of prior hospitalizations and a longer duration 
of follow-up.  Compared to subjects with 1 to 3 months of follow-up, the OR of optimal 
adherence was 0.16 (95% CI 0.13-0.20) with 3 to 6 months of follow-up and 0.04 (95% CI 0.03-
0.05) with greater than 2 years of follow-up.  The small magnitude of these odds ratios reflects 
the high degree of adherence in the first 3 months of follow-up.  The percentage of individuals 
with less than 3 months of follow-up achieving optimal adherence was 85% while the 
corresponding result was 30% for those with follow-up more than 2 years.  
The remaining variables in the model only had modest predictive power, with odds ratios 
ranging between 0.8 and 1.2.  The odds of adherence increased with female sex (OR 1.12, 95% 
CI 1.03-1.22) and a recent index year (OR 1.06 in 2005/06; OR 1.19 in 2009/10).  However, 
subjects in the latest index years had the shortest duration of follow-up (mean follow-up 1148 
days and 306 days in 2003/04 and 2009/10, respectively), so this result may be biased.  Being a 
VKA user in the prior year decreased the likelihood of adherence (OR 0.81, 95% CI 0.71-0.92).  
Adherence also appeared to be worse among those taking 3 or more non-cardiovascular drugs 
(OR 0.77, 95% CI 0.67-0.88), and those with a greater extent of comorbidity (≥3 vs. 0 prior 
hospitalizations OR 0.70, 95% CI 0.59-0.83; Charlson index ≥3 vs. 0 OR 0.89, 95% CI 0.78-
1.02). 
Table 4.13 Odds Ratios (OR) of Optimal Adherence for Variables in the Empiric Model 
(Using 80% Adherence Threshold) 
Effect OR 95% CI 
Age (<75 yrs.)  --- --- 
Sex (Female) 1.12 1.03-1.22 
Rural --- --- 
Income quintiles   
2 vs. 1 1.09 0.96-1.24 
3 vs. 1 1.04 0.91-1.18 
4 vs. 1 1.04 0.91-1.18 
5 vs. 1 1.14 0.99-1.31 
Physician visit   
12-18 vs. 0-11 1.15 1.01-1.30 
19-25 vs. 0-11 1.29 1.13-1.48 
26-36 vs. 0-11 1.29 1.12-1.49 
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Effect OR 95% CI 
≥37 vs. 0-11 1.51 1.28-1.77 
Hospitalizations   
1 vs. 0 0.94 0.85-1.04 
2 vs. 0 0.86 0.74-0.98 
≥3 vs. 0 0.70 0.59-0.83 
Charlson   
1 vs. 0 1.02 0.92-1.13 
2 vs. 0 0.84 0.74-0.95 
≥3 vs. 0 0.89 0.78-1.02 
Prior diabetes 
No vs. Yes 
 
1.11 
 
1.00-1.22 
Non-CV drugs   
1 vs. 0 0.93 0.85-1.02 
2 vs. 0 0.99 0.88-1.11 
≥3 vs. 0 0.77 0.67-0.88 
Practitioner Type  
GP vs. SP 
 
2.72 
 
0.88-8.40 
Indication   
Other vs. AF --- --- 
Multi vs. AF --- --- 
PHV vs. AF --- --- 
VTEP vs. AF --- --- 
VTE vs. AF --- --- 
Follow-up (days)   
91-180 vs. 35-90 0.16 0.13-0.20 
181-365 vs. 35-90 0.09 0.08-0.11 
366-730 vs. 35-90 0.06 0.05-0.07 
≥731 vs. 35-90 0.04 0.03-0.05 
Recent vs. new VKA use 0.81 0.71-0.92 
Index year   
2005-06 vs. 03-04 1.06 0.95-1.18 
2007-08 vs. 03-04 1.20 1.07-1.34 
2009-10 vs. 03-04 1.19 1.04-1.36 
--- The variable is a part of an interaction term, for which the odds ratios are listed separately in 
Table 4.14. 
4.5.4 Interactions 
A significant interaction was identified between age and urban/rural residence; however, 
age did not appear to modify the impact of rural status in a meaningful way (Table 4.14).  The 
odds of optimal adherence among individuals living in rural areas was decreased by 36.5% for 
individuals <75 years of age and by 44.8% for individuals ≥75.  The strength of this association 
is also clinically meaningful, and suggests that rural residents may have poorer access to INR 
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monitoring overall.    
Several other significant interactions were identified in the model (Table 4.14).   
However, most of the interactions did not appear to represent meaningful effect modification.  
The largest effect modification was observed between age and indication for VKA therapy (i.e., 
diagnosis).  However, no consistent pattern could be identified with respect to this finding. 
Table 4.14 Odds Ratios (OR) for the Interaction Terms in the Empiric Models 
Variables held constant Comparison OR 95% CI 
Age <75 yrs. ------------------ Rural vs. Urban 0.64 0.55-0.73 
Age ≥75 yrs. ------------------ Rural vs. Urban 0.55 0.47-0.64 
Urban Other Age <75 yrs. vs. ≥75 yrs. 0.83 0.71-0.98 
Rural Other Age <75 yrs. vs. ≥75 yrs. 0.96 0.80-1.16 
Urban Multi Age <75 yrs. vs. ≥75 yrs. 1.14 0.82-1.59 
Rural Multi Age <75 yrs. vs. ≥75 yrs. 1.31 0.93-1.85 
Urban PHV Age <75 yrs. vs. ≥75 yrs. 1.61 0.83-3.10 
Rural PHV Age <75 yrs. vs. ≥75 yrs. 1.85 0.96-3.57 
Urban VTEP Age <75 yrs. vs. ≥75 yrs. 1.49 0.90-2.47 
Rural VTEP Age <75 yrs. vs. ≥75 yrs. 1.72 1.04-2.86 
Urban VTE Age <75 yrs. vs. ≥75 yrs. 0.88 0.72-1.08 
Rural VTE Age <75 yrs. vs. ≥75 yrs. 1.01 0.81-1.26 
Urban AF Age <75 yrs. vs. ≥75 yrs. 0.87 0.76-1.00 
Rural AF Age <75 yrs. vs. ≥75 yrs. 1.00 0.86-1.17 
Age <75 yrs. ------------------ Other vs. AF 0.83 0.73-0.95 
Age ≥75 yrs. ------------------ Other vs. AF 0.87 0.75-1.01 
Age <75 yrs. ------------------ Multi vs. AF 1.22 0.96-1.57 
Age ≥75 yrs. ------------------ Multi vs. AF 0.93 0.73-1.19 
Age <75 yrs. ------------------ PHV vs. AF 1.32 0.97-1.79 
Age ≥75 yrs. ------------------ PHV vs. AF 0.71 0.39-1.29 
Age <75 yrs. ------------------ VTEP vs. AF 1.07 0.70-1.61 
Age ≥75 yrs. ------------------ VTEP vs. AF 0.62 0.45-0.86 
Age <75 yrs. ------------------ VTE vs. AF 1.13 0.98-1.30 
Age ≥75 yrs. ------------------ VTE vs. AF 1.12 0.93-1.34 
 
4.5.5 Sensitivity Analysis 
 In the sensitivity analysis, few changes to the odds ratios were observed when we 
modified the adherence thresholds to 60% and 100% (Table 4.15).  The most notable differences 
were in the estimates for PHV (80% threshold OR 0.72, 95% CI 0.40-1.30; 100% threshold OR 
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1.07, 95% CI 0.58-1.97, among subjects age ≥75 years) and VTEP (60% threshold OR 0.82, 
95% CI 0.60-1.12; 100% OR 1.24, 95% CI 0.92-1.69, among subjects age <75 years); however, 
the clinical importance of these differences is not known.   
Table 4.15 Sensitivity Analysis of 80% Adherence Threshold - Parameter Estimates of Full 
Model Compared to 60% and 100% Adherence Thresholds 
 80% threshold 60% threshold 100% threshold 
Effect OR 95% CI OR 95% CI OR 95% CI 
Intercept 2.12 0.66 - 6.82 10.26 3.13 - 33.61 0.86 0.23 - 3.24 
Age (<75 yrs.) --- --- --- --- --- --- 
Sex (Female) 1.12 1.03 - 1.22 1.07 0.98 - 1.16 1.06 0.94 - 1.18 
Rural --- --- --- --- --- --- 
Income quintile       
2 vs. 1 1.09 0.96 - 1.24 1.20 1.05 - 1.37 1.08 0.91 - 1.29 
3 vs. 1 1.04 0.91 - 1.18 1.20 1.06 - 1.37 1.06 0.89 - 1.26 
4 vs. 1 1.04 0.91 - 1.18 1.14 0.99 - 1.30 1.02 0.85 - 1.23 
5 vs. 1 1.14 0.99 - 1.31 1.19 1.03 - 1.37 1.15 0.96 - 1.39 
Physician visit       
12-18 vs. 0-11 1.12 0.97 - 1.28 1.13 0.98 - 1.29 1.07 0.88 - 1.30 
19-25 vs. 0-11 1.28 1.09 - 1.50 1.34 1.14 - 1.57 1.24 0.99 - 1.56 
26-36 vs. 0-11 1.32 1.11 - 1.56 1.48 1.24 - 1.78 1.24 0.97 - 1.57 
≥37 vs. 0-11 1.58 1.29 - 1.92 1.63 1.33 - 2.00 1.64 1.25 - 2.15 
Hospitalization       
1 vs. 0 0.94 0.84 - 1.05 0.97 0.87 - 1.09 0.97 0.83 - 1.14 
2 vs. 0 0.87 0.75 - 1.01 0.90 0.77 - 1.06 0.90 0.73 - 1.11 
≥3 vs. 0 0.72 0.60 - 0.86 0.80 0.67 - 0.96 0.80 0.62 - 1.03 
Charlson       
1 vs. 0 1.00 0.90 - 1.11 0.98 0.87 - 1.09 0.88 0.76 - 1.02 
2 vs. 0 0.84 0.73 - 0.95 0.93 0.81 - 1.06 0.81 0.68 - 0.97 
≥3 vs. 0 0.89 0.78 - 1.03 0.92 0.80 - 1.06 0.76 0.62 - 0.92 
Diagnoses       
7-10 vs. 0-6 1.09 0.96 - 1.25 1.13 0.99 - 1.30 1.04 0.86 - 1.25 
11-16 vs. 0-6 0.97 0.82 - 1.14 0.99 0.84 - 1.18 0.93 0.74 - 1.16 
≥17 vs. 0-6 0.90 0.74 - 1.10 0.89 0.72 - 1.10 0.75 0.57 - 0.99 
Prior diabetes 
No vs. Yes 1.13 1.02 - 1.26 1.25 1.12 - 1.39 1.05 0.90 -­‐1.22 
Prior stroke 
No vs. Yes 0.87 0.73 - 1.04 0.94 0.79 - 1.12 0.90 0.69 -­‐ 1.17 
CV drugs       
1 vs. 0 1.05 0.90 - 1.22 1.17 1.00 - 1.38 1.00 0.82 - 1.21 
2 vs. 0 1.08 0.93 - 1.26 1.23 1.05 - 1.44 1.01 0.82 - 1.24 
3 vs. 0 1.12 0.95 - 1.31 1.23 1.05 - 1.45 1.08 0.88 - 1.34 
≥4 vs. 0 1.14 0.99 - 1.32 1.22 1.05 - 1.42 1.15 0.95 - 1.40 
Non-CV drugs       
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 80% threshold 60% threshold 100% threshold 
Effect OR 95% CI OR 95% CI OR 95% CI 
1 vs. 0 0.93 0.84 - 1.02 0.95 0.86 - 1.04 0.93 0.82 - 1.06 
2 vs. 0 0.99 0.88 - 1.12 0.86 0.76 - 0.97 1.02 0.87 - 1.20 
≥3 vs. 0 0.77 0.67 - 0.89 0.80 0.69 - 0.92 0.97 0.80 - 1.17 
Pract. Type 
GP vs. SP 2.74 0.89 - 8.49 2.81 0.91 - 8.68 2.77 0.79 -­‐ 9.78 
Indication       
Other vs. AF --- --- --- --- --- --- 
Multi vs. AF --- --- --- --- --- --- 
PHV vs. AF --- --- --- --- --- --- 
VTEP vs. AF --- --- --- --- --- --- 
VTE vs. AF --- --- --- --- --- --- 
Follow-up (days)       
91-180 vs. 35-90 0.16 0.13 - 0.20 0.09 0.06 - 0.12 0.15 0.13 - 0.18 
181-365 vs. 35-90 0.09 0.08 - 0.11 0.04 0.03 - 0.05 0.06 0.05 - 0.07 
366-730 vs. 35-90 0.06 0.05 - 0.07 0.02 0.02 - 0.03 0.02 0.02 - 0.03 
≥731 vs. 35-90 0.04 0.03 - 0.04 0.02 0.01 - 0.02 0.00 0 - 0.01 
Recent vs. new 
VKA use 0.80 0.71 - 0.91 0.84 0.74 - 0.96 1.11 0.92 - 1.33 
Index year       
2005-06 vs. 03-04 1.05 0.95 - 1.17 0.95 0.85 - 1.06 1.11 0.95 - 1.30 
2007-08 vs. 03-04 1.19 1.07 - 1.34 1.14 1.02 - 1.28 1.06 0.90 - 1.25 
2009-10 vs. 03-04 1.18 1.03 - 1.34 1.17 1.01 - 1.35 1.05 0.89 - 1.24 
Age*Indication       
<75 yrs. *other --- --- --- --- --- --- 
<75 yrs. *multi --- --- --- --- --- --- 
<75 yrs. *PHV --- --- --- --- --- --- 
<75 yrs.* VTEP --- --- --- --- --- --- 
<75 yrs. * VTE --- --- --- --- --- --- 
Age *Urban/Rural --- --- --- --- --- --- 
<75 yrs.*Rural --- --- --- --- --- --- 
---  ORs not reported for interaction terms. 
 48 
5 DISCUSSION 
This retrospective cohort study examined adherence to INR testing among 17,388 
individuals in Saskatchewan receiving anticoagulation with VKA medications between 2003 and 
2010.  The most frequently identified indications for VKA therapy were AF (34%) and VTE 
(14%), accounting for almost one-half of all patients examined.  Altogether, 42% of the studied 
population resided in rural areas and virtually all patients (99%) appeared to be monitored by a 
general practitioner.  Following the first dispensation for a VKA, the median interval until the 
first INR claim date was 26 days.  During a median follow-up of 514 days, 50% of patients 
exhibited at least 74% adherence to INR testing if a 4-week interval was used as the reference 
standard.  However, the estimated median adherence increased dramatically to 98% when the 
benchmark for optimal testing was lengthened to every 12 weeks, suggesting that most gaps in 
testing occurred during intervals that were between 4 and 12 weeks long.  Further, very few 
cases of non-persistence to INR testing were identified, suggesting most patients continue testing 
while receiving VKAs, albeit sometimes at a lower frequency.  The most prominent risk factors 
for non-adherence to INR monitoring appear to be rural residence and duration of VKA therapy.      
The median adherence to INR testing (74%) using a 4-week test interval is lower than 
what has been reported in several studies, and only 44% of subjects achieved at least 80% 
adherence.  It has been estimated that between 70% and 90% of VKA patients were monitored at 
least monthly in previously published study populations (52,72,82).  However, these results may 
not reflect real world practice because these data were collected from a physician questionnaire 
(82), from a commercially insured population (52), or had a short duration of follow-up (72).  
Although the study cohort we identified from Saskatchewan was not testing as frequently as 
published estimates, median adherence in our cohort approached 100% when a 12-week testing 
interval was used as the reference standard.  Also, when a more strict definition of continuous 
VKA therapy was used to define the follow-up period (51 days vs. 150 days), median adherence 
improved to 90%.  The result of this sensitivity analysis suggests that a portion of INR non-
adherence identified in the primary analysis may have been misclassified due to temporary 
discontinuations of VKA therapy when INR monitoring was not required.  Finally, virtually no 
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evidence of non-persistence to INR monitoring could be identified.  It would seem that patients 
do not quit INR testing until the VKA has been discontinued.  
Based on the results from the primary analyses and sensitivity testing, it would appear 
that VKA therapy is being regularly monitored.  However, it must be recognized that the study 
cohort was made up of individuals with at least one INR monitoring claim.  In fact, almost 50% 
of all eligible episodes were excluded due to no recorded physician service claim for INR testing 
during the entire duration of VKA therapy.  Although these patients may represent a complete 
lack of adherence to INR monitoring, it is also possible they are being managed by prescribers 
who are not reimbursed by the fee-for-service model.  Alternatively, some practitioners may not 
bill for anticoagulation monitoring.  Future studies should attempt to capture actual INR testing 
claims through laboratory databases in order to discriminate between these possible scenarios.  
At the time of this study, laboratory data was not accessible.       
One of the most striking predictors of adherence in the multivariable model was duration 
of VKA use.  The median adherence of patients in the first 3 months of VKA therapy was 86% 
compared to 62% beyond 2 years of therapy.  The only other study to have investigated this 
association did not find that the length of VKA therapy was a predictor of non-adherence (OR 
1.00, 95% CI 0.99-1.01) (94).  However, a key difference is that our cohort was made up of 
mostly new users to VKA therapy.  Therefore, declining adherence could be partly explained by 
the discontinuation of VKA therapy in patients who could not achieve stable INR levels early on.  
Thus, over time the patients that remain on therapy may have relatively stable responses to VKA 
medications and require less frequent INR testing.  Stable VKA therapy is now an accepted 
reason to extend INR testing intervals as long as 12 weeks (49).  At the time of proposing this 
project, INR testing was recommended at 4-week intervals regardless of previous testing results 
(1).  
Rural residence was significantly associated with lower adherence to INR monitoring.  
Approximately one-third of rural residents achieved the threshold for optimal adherence, 
compared to one-half of urban residents.  A possible explanation of poor adherence in this 
subgroup could be reduced access to testing facilities or a shortage of physicians in rural centers.  
More research would be needed to understand the exact nature of this association.  The current 
data was restricted to two levels of residence, urban and rural only.  Urban residence was defined 
as a Census Metropolitan Area or Census Agglomeration according to Statistics Canada (127).  
 50 
Ideally, it would be useful to identify the locations of laboratory testing facilities and healthcare 
providers to determine if access was indeed the underlying cause of this association.  Also, it is 
possible that rural residence may be a marker of other patient characteristics such as low 
socioeconomic status (105).     
Despite the theoretical challenges with monitoring INR levels in rural areas, it appears 
that VKA therapy is frequently prescribed in this population because a relatively large proportion 
of the study cohort were rural residents (42%).  A recent study suggests that there may be a 
greater risk of using anticoagulants in patients residing in rural areas.  Shepherd and colleagues 
reported that the risk of death due to an adverse drug reaction was twice as high in rural areas 
compared to urban centers, and that anticoagulants were among the most responsible drug 
classes (141).  It would be of interest to investigate if poor adherence to INR testing in rural 
areas translates into adverse health outcomes. 
Our results suggest that subjects with an indication of VTEP or PHV may have an 
increased odds of adherence compared to those with AF.  Median adherence was approximately 
20% better among subjects with PHV (88.4%) and VTEP (90.5%) compared to those with AF 
(70.9%).  This observation might be partly explained by the shorter duration of follow-up in 
these groups.  The median duration of follow-up for subjects with AF was 755 days, compared to 
only 107 days with VTEP and 259 days for PHV.  Shorter duration of use for VTEP and PHV 
are expected given that the excess risk of clotting may be temporary following orthopedic 
surgeries (20) and procedures for bioprosthetic valve replacement (19).  Nonetheless, the high 
frequency of good adherence in the PHV group is reassuring given that many of these patients 
require a greater intensity of anticoagulation (i.e., have a higher INR target) compared to other 
indications (19).   
5.1 Limitations 
 To our knowledge this descriptive analysis is the first to examine adherence to INR 
testing in a real-world population.  Despite the great potential to understand VKA use, there are 
several limitations to consider.  Most notably, physician fee-for-service claims for anticoagulant 
monitoring were used as a proxy for INR testing.  As a consequence, a large number of episodes 
were excluded because no INR claims were recorded in the MSB.  There are a variety of 
situations in which a subject could have been measuring their INR where it was not captured, 
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including testing at anticoagulation clinics, during periods of hospitalization, monitoring by a 
salaried physician, and where fee-for-service physicians might not submit a claim at all.  Due to 
limitations in the data source, at least one INR claim was required to rule out these other 
scenarios.  The results of this study must be interpreted with caution because it is possible that 
many patients receive VKA medications without INR monitoring.  Certainly, inclusion of these 
patients would drastically modify the results observed in the current study cohort.  It is 
anticipated that laboratory testing results will become available in the future.  At that time, these 
data should be re-analyzed using the actual INR test results for all patients, regardless of 
physician claim status.     
 Another concern was the high number and proportion of VKA episodes that did not meet 
any of the case definitions for a disease group (29%).  Several different strategies were used to 
attempt to capture a common indication for these missed episodes, as discussed in the results’ 
section.  These included a review of the frequency of diagnostic codes in the DAD and the MSB 
near the date of the first VKA dispensation, and expanding the criteria for an AF diagnosis to 
capture records in the prior year.  However, none of these methods successfully identified a 
predominant diagnosis.  Given that the records from emergency room (ER) visits were not 
available, our speculation is that a number of these subjects could have been diagnosed with a 
DVT in the ER and never admitted to the hospital.  Capturing ER visit records and diagnoses 
would be the next recommended step to identify reasons for VKA therapy among study patients.    
There are limitations to several of the explanatory variables we used in our models.  We 
used validated case definitions wherever possible to categorize subjects based on their indication, 
but none of these were specifically validated in a population of anticoagulation users.  Both 
income quintile and area of residence were assigned based on the subject’s dissemination area 
from the 2006 Statistics Canada Census, and are not reported for each individual.  Subjects were 
considered urban residents if they were living in a Census Metropolitan Area or Census 
Agglomeration with 10,000 or more people (127), while all others were categorized as rural.  
One limitation of this is that the definition of rural resident does not consider the extent of 
isolation or proximity to health services.  Future work should attempt to subdivide this 
population based on travel distance to a general practitioner or hospital. 
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There were challenges to the assignment of VKA exposure that could have influenced 
our findings as well.  Our definition for the discontinuation of VKA therapy is complicated by 
frequent dose adjustments, which make it difficult to estimate a days’ supply.  Also, refill 
compliance measures are not useful for drugs with frequent dosage changes (114).  We 
addressed this by performing sensitivity analyses around the definition of discontinuation.  The 
gaps between INR measurements could also be a result of the temporary discontinuation of the 
VKA, as suggested by van Walraven et al. (8).  This could inflate the CMG, and ultimately 
underestimate adherence to INR monitoring.  Lastly, we did not remove the time that subjects 
spent in hospital from their follow-up.  Given that physician claims would not be captured over 
these time periods, this could also underestimate adherence. 
The final limitation to consider is that the 80% adherence threshold has not been 
validated against outcomes.  However sensitivity analyses were conducted around this level, and 
the estimates did not change noticeably.  Future work could consider the clinical impact of 
different thresholds of INR adherence.  Prior research has suggested that non-adherence to INR 
testing increases the risk of thromboembolism by approximately 50% compared to good 
adherence.  However, in this study subjects were considered non-adherent if they missed only 2 
consecutive scheduled INR tests at the anticoagulation clinic at which they were followed (94).  
This definition does not provide a measure of the extent of non-adherence as the CMG does.  It 
would be of interest to determine if varying levels of adherence affect clinical outcomes 
differently. 
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6 CONCLUSION 
This study provides some of the first insights into the nature of anticoagulation 
monitoring among community living patients in Saskatchewan, most of who were not managed 
by specialty providers.  Overall, adherence to INR testing appeared generally acceptable; 
especially when a 12-week testing interval was used as the reference standard.  Moreover, very 
few patients quit INR testing until the VKA therapy had been terminated.  An association 
between rural residence and poor INR testing adherence was observed, but the true nature of this 
association could not be determined.  Further research into the determinants of INR adherence in 
rural versus urban settings should be conducted to identify specific targets for improving 
anticoagulation success in the province.  Specifically, understanding the quality of INR testing 
will help inform the rational use of new oral anticoagulant medications that are very costly but 
can be administered without the need for regular testing. 
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APPENDIX A – List of Cardiovascular and Non-cardiovascular Medications 
Cardiovascular drugs 
Antihypertensive agents 
   acebutolol indapamide telmisartan minoxidil 
amiloride/HCTZ irbesartan telmisartan/HCTZ oxprenolol 
amlodipine irbesartan/HCTZ timolol pindolol 
atenolol lisinopril timolol / HCTZ pindolol/HCTZ 
atenolol/chlorthalidone lisinopril/HCTZ trandolapril prazosin 
benazepril losartan triamterene/HCTZ reserpine 
candesartan losartan/HCTZ valsartan 
reserpine/chlorthal
idone 
candesartan/HCTZ metolazone valsartan/HCTZ reserpine / HCTZ 
captopril metoprolol verapamil 
reserpine/HCTZ/h
ydralazine 
chlorthalidone metoprolol/HCTZ amiloride spironolactone 
cilazepril nadolol clonidine 
spironolactone/HC
TZ 
cilazepril/HCTZ nifedipine SR debrisoquine terazosin 
diltiazem perindopril doxazosin bumetanide  
enalapril perindopril/indapamide guanethidine ethacrynic acid  
enalapril/HCTZ propranolol hydralazine furosemide 
eprosartan propranolol / HCTZ labetolol triamterene 
felodipine quinapril methyldopa 
 fosinopril quinapril/HCTZ methyldopa/CTZ 
 hydrochlorothiazide (HCTZ) ramipril methyldopa/HCTZ  
Cardiac agents 
   amiodarone  erythrityl tetranitrate nicardipine propafenone 
bisoprolol  flecainide nifedipine regular quinidine 
carvedilol  isosorbide dinitrate nimodipine (EDS) sotalol 
digoxin isosorbide mononitrate nitroglycerin tocainide 
disopyramide mexiletine procainamide   
Diabetes agents 
   acarbose insulin repaglinide (EDS) 
 acetohexamide metformin rosiglitazone (EDS) 
 chlorpropamide nateglinide (EDS) tolbutamide 
 gliclazide (NF) phenformin 
  glyburide pioglitazone (EDS) 
  Lipid lowering agents       
atorvastatin lovastatin cholestyramine fenofibrate 
cerivastatin pravastatin clofibrate gemfibrozil 
rosuvastatin simvastatin colestipol 
niacin 500 mg tablet 
(nicotinic acid) 
fluvastatin bezafibrate (EDS) ezetimibe probucol 
Anticoagulants       
dalteparin (EDS) heparin tinzaparin (EDS) 
 enoxaparin (EDS) nadroparin (EDS) 
  Antiplatelets       
dipyridamole (EDS) ASA ticlopidine (EDS) 
 dipyridamole/ASA (EDS) clopidogrel (EDS) sulfinpyrazone 
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Non-cardiovascular drugs 
Hormone replacement 
therapy 
   
oral conjugated estrogen 
estradiol & 
norethindrone/estradiol 
(EDS) estropipate 
 
conjugated 
estrogen/medroxyprogesterone estradiol valerate 
oral 
medroxyprogesteron
e 
 oral and transdermal estradiol 
(EDS) 
estradiol/norethindrone 
(EDS) 
progesterone 
micronized (EDS) 
 NSAIDs       
ASA cpd. With codeine fenoprofen mefenamic acid rofecoxib (EDS) 
celecoxib (EDS) floctafenine meloxicam (EDS) sulindac 
diclofenac flurbiprofen nabumetone (EDS) tiaprofenic acid 
diclofenac/misoprostol ibuprofen naproxen tolmetin 
diflunisal indomethacin phenylbutazone zomepirac 
etodolac (EDS) ketoprofen piroxicam 
 Antidepressants       
amitriptyline doxepin moclobamide escitalopram  
amoxapine fluoxetine nefazodone trazodone 
bupropion (EDS) fluvoxamine nortriptyline venlafaxine 
citalopram imipramine paroxetine duloxetine  
clomipramine maprotiline trimipramine desvenlafaxine 
desipramine mirtazapine sertraline 
 Antipsychotics        
chlorpromazine mesoridazine trifluoperazine risperidone 
flupenthixol pericyazine ziprasidone  clozapine (EDS) 
fluphenazine perphenazine zuclopenthixol olanzapine (EDS) 
fluspirilene pimozide aripiprazole  
 haloperidol pipotiazine paliperidone  
 loxapine prochlorperazine quetiapine 
 Glucocorticosteroids       
beclomethasone budesonide hydrocortisone 
 
betamethasone 
budesonide / formoterol 
(EDS) methylprednisolone 
 cortisone dexamethasone 
  Migraine agents       
Cafergot-PB flunarizine rizatriptan 
 
dihydroergotamine mesylate 
methysergide bimaleate 
(EDS) sumatriptan  
 ergotamine tartrate naratriptan (EDS) zolmitriptan  
 ergotamine/caffeine pizotyline 
  ergotamine/cyclizine/caffeine almotriptan 
  Bisphosphonates       
alendronate (EDS) etidronate/calcium risedronate  
 etidronate pamidronate (EDS) zoledronic acid 
 Uric acid agents       
allopurinol colchicine probenecid 
 Proton pump inhibitors       
esomeprazole (EDS) omeprazole (EDS) rabeprazole (EDS) 
 lansoprazole (EDS) pantoprazole (EDS) 
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H2-receptor antagonists       
cimetidine misoprostol ranitidine 
 
famotidine nizatidine 
ranitidine bismuth 
citrate 
 Other gastrointestinal agents       
lansoprazole/clarithromycin/a
moxicillin (EDS) pirenzepine sucralfate 
 Transplant agents       
cyclosporine (EDS) sirolimus (EDS) 
  mycophenolate (EDS) tacrolimus (EDS)     
 
 
